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ABSTRACT
Mammalian noses can detect and distinguish an inestimable number of odors at
minute concentrations. Four classes of G protein-coupled receptors (GPCRs) are
responsible for this remarkable sensitivity: olfactory receptors (ORs), vomeronasal
receptors (VNRs), trace amine-associate receptors, and formyl peptide receptors.
Structural knowledge of these receptors is necessary to understand the molecular
basis of smell. However, no structure exists for three main reasons. First, milligrams of
protein are needed for crystallization screens, but most are expressed at low levels
endogenously or in heterologous expression systems. Second, detergents capable of
solubilizing and stabilizing these proteins in aqueous solution must be found. Third, the
flexible nature of GPCRs can inhibit crystal lattice formation.
Methods for overcoming each obstacle were developed. Milligrams of a VNR were
expressed in HEK293 cells, and milligrams of 13 GPCRs were expressed in a cell-free
system. All could be purified to >90%. The purified receptors had correct secondary
structures, and could bind their ligands. The HEK293 and cell-free receptors had nearly
identical structures and binding affinities, demonstrating that cell-free expression can be
used for GPCR production and mutational studies. To demonstrate this, six variants of
mOR103-15 with single amino acid substitutions were expressed. Ligand-binding
measurements indicated which residues were involved in ligand recognition. The choice of
detergent used in the cell-free system was critical, and significantly affected expression
levels. A class of amphiphilic peptide detergents was designed and tested with the
receptors. These detergents could be used to express milligrams of functional receptors.
The peptide tail and head group properties did not significantly affect their function,
suggesting that they may be a class of surfactants usable with multiple olfactory-related
receptors, and even other membrane proteins. Lastly, the protein T4 Lysozyme (T4L) was
fused in the 3rd intracellular loop of two receptors to increase potential crystal lattice
contact points. Purified T4L variants had correct secondary structures, and could bind
their ligands and initiate intracellular signaling. The methods described generated
sufficient quantities of pure receptors for crystal screens. The large number of functionally
expressed GPCRs indicates that these techniques can be applied to other olfactory-related
receptors, and even other membrane proteins.
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CHAPTER 1
INTRODUCTION AND BACKGROUND
1.1 G Protein-Coupled Receptors
1.1.1 Overview
G protein-coupled receptors (GPCRs) are the largest class of membrane proteins.
They are involved in many physiological processes, including sight, smell, inflammation,
and regulation of the nervous system. Because of the broad range and significance of their
functions, GPCRs are involved in many diseases and are the target of over 50% of
pharmaceutical drugs [1, 2]. In spite of their importance, relatively little is known about
their structure and function.
The GPCR family of proteins is characterized by a common three-dimensional
structure and similar signaling pathways. GPCRs have seven transmembrane a-helical
domains joined by flexible loops, an extracellular N-terminus, and an intracellular C-
terminus. The transmembrane domains are arranged in a barrel-like configuration (Figure
1.1). Ligands bind primarily in the pocket formed from the helix barrel, but they can also
bind to the N-terminus or the extracellular loops [3]. Upon ligand binding, the receptor
changes conformation and activates a G-protein. The activated G-protein initiates a
signaling cascade, where the specific pathway depends on the specific G-protein. p-
arrestins may also act as signal transducers instead of a G-protein [4-7]. The structural and
signaling similarities among GPCRs are surprising, considering that sequence identity
among individual family members can be less than 20% [8,9].
NH2
Cytoplasm
Ligand
G-Protein
Figure 1.1. Schematic Representation of a GPCR. GPCRs have seven transmembrane helices
arranged in a barrel-like configuration, represented by cylinders. The ligand binds in the pocket
formed by the helices on the extracellular side. Upon binding, the GPCR undergoes a
conformational change and initiates a signaling cascade through a G-protein on the intracellular
surface.
1.1.2 Receptors Involved in Olfaction
There are four main classes of GPCRs that are involved in olfaction: olfactory
receptors (ORs) [10], trace amine-associate receptors (TAARs) [11], vomeronasal
receptors (VNRs) [12, 13], and formyl peptide receptors (FPRs) [14, 15]. All are GPCRs.
Together, they comprise the largest subclass of GPCRs, and account for -3% of the
mammalian genome.
1.1.3 Olfactory Receptors
Olfactory receptors are the largest of the four classes of receptors, and are in fact the
largest gene family in vertebrates [16]. Humans have up to -1000 receptors, of which 391
are functional and the remaining are pseudogenes. In contrast, mice and dogs are
predicted to have -1000 functional receptors, and only 200-300 pseudogenes [8, 17-22].
Olfactory receptors are divided into two classes based on sequence homology. Class
I receptors are genetically similar to amphibian ORs, and typically bind water-soluble
ligands. Class 11 receptors constitute the majority of mammalian ORs, and bind volatile
hydrophobic molecules. All ORs are -30-35 kDa, while their ligands are all less than 300
Da [21, 23, 24].
Studies indicate that mammalian noses can detect a seemingly infinite number of
odorants in minute concentrations as small as parts per trillion [25]. This amazing
sensitivity is made possible through the organization of the olfactory system. Olfactory
receptors are expressed on the cilia of olfactory neurons in the main olfactory epithelium
(MOE) [26]. The MOE is divided into 4 sections. Each neuron expresses only one OR allele,
and all neurons expressing the same allele are spread throughout the same MOE section
[27-29]. Axons of neurons expressing the same OR meet at foci called glomeruli [29, 30].
Because each receptor recognizes specific chemical groups on odorants, one odorant can
activate many receptors, and one receptor can bind several odorants [31, 32] (Figure 1.2).
Signals from activated neurons converge onto the appropriate glomeruli, creating a spatial
map that is believed to encode a scent's identity [8, 31]. This combinatorial method of
signal detection allows the number of detectable odors to greatly exceed the number of
ORs in the genome. Because only portions of an odorant are identified by each receptor,
the olfactory system can detect new molecules that have not been previously encountered
in the course of evolution.
A B
ODOFNMT RECEPTORS
odorant
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receptors
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M M.
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E M MEin brain)
Figure 1.2. Combinatorial Coding of Olfactory Receptors. A) Each receptor can recognize
specific chemical groups on an odorant. Thus, one odorant can activate multiple receptors, and
each receptor can bind to several odorants. Reprinted from [31] with permission from Elsevier. B)
The axons of neurons that express the same receptor converge into foci called glomeruli. The
spatial map of activated glomeruli encodes a unique odor. From [132], by permission of Oxford
University Press.
Olfactory receptors transduce signals through the G-protein Gol. Upon ligand
binding, Goif is activated and released. The released G-protein subunit stimulates Adenylate
Cyclase III to increase cAMP production, which further triggers ion-channel mediated Ca+2
release and firing of an action potential [26, 33-36] (Figure 1.3). Olfactory receptors are
capable of interacting with other G-proteins, thus enabling receptor activity to be measured
in vitro using heterologous cell expression [8, 32, 37].
Odorant
fldorant
C8I2t' Na+ CI -
~z, Li
Figure 1.3. Olfactory Receptor Signal Transduction. Upon odorant binding, the G-protein is
activated and released. Cyclic-AMP production is increased, which induces an influx of Ca+2 and
firing of an action potential. Reprinted from [36] with permission from Macmillan Publishers Ltd,
@2004.
Although olfactory system morphology and signal transduction have been studied,
very little is known about the molecular basis of olfaction. Only a handful of ORs have been
deorphaned [8]. Due to the difficulty of working with this class of receptors, only three
mutational studies investigating potential ligand-binding sites have been performed [38-
40]. All other studies have been computational. Several studies have developed OR
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structures based on homology modeling to bacteriorhodopsin or vertebrate rhodopsin [41-
47]. Others are based on comparisons between OR orthologs, homologs, and conserved or
variable sequence motifs [48-50]. Although the mutational and computation studies yield
insights into OR function, it is not possible to predict with certainty which ligands will bind
a specific receptor. It is also not possible to predict the "scent" of a molecule. In order to
understand this molecular basis of smell, knowledge of the structure of an OR is critical, as
well as a deeper understanding of the combinatorial code.
1.1.4 Trace Amine-Associate Receptors
Trace amine associate receptors (TAARs) are a small class of GPCRs that detects
small volatile amines implicated in social signaling [11, 51]. Most species have less than 30
genes, with humans having 7 functional receptors and mice having 15. In mice, TAARs are
likely involved in detecting social cues [15].
Trace-amine associate receptors are expressed in the main olfactory epithelium
alongside ORs. Like ORs, each TAAR gene appears to be expressed within a specific
epithelial zone. Evidence also indicates that each neuron expresses only one TAAR gene,
and that TAARs are not co-expressed with ORs [11]. Labeling experiments demonstrated
that the G-protein Golf is co-expressed with TAARs. Ligand activation of TAARs increases
cAMP levels, suggesting that TAARs utilize the same signaling pathway as ORs [11, 52, 53].
Although both ORs and TAARs detect small volatile compounds, exhibit similar
expression patterns, and activate the same signaling messengers, they are unique GPCR
families. Sequence homology between the two GPCR classes does not exceed 16% [8, 11].
Also, TAARs do not have the same sequence motifs seen in the OR family.
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1.1.5 Vomeronasal Receptors
Vomeronasal receptors (VNRs) detect pheromones and molecules involved in social
signaling. They are divided into two classes based on their structure and ligands. Type 1
VNRs (VN1Rs) have short N- and C-termini, and bind small volatile ligands. Type 2 VNRs
(VN2Rs) have an extended N-terminus, and bind peptides [12, 13, 36, 54, 55] (Figure 1.4).
Like ORs, only one unique VNR allele is expressed in a neuron, and neurons expressing the
same VNR converge to the same glomeruli [36].
NH2
NH2
AB
COOH COOH
Figure 1.4. Vomeronasal Type 1 and Type 2 Receptor Structures. A) Type 1 receptors have
structures similar to ORs, while B) Type 2 receptors have an extended N-terminus. Reprinted from
[36] with permission from Macmillan Publishers Ltd, ©2004.
Human and rodent VNRs likely serve different roles. Mice have 100-200 potentially
functional VN1Rs, and about 100 VN2Rs. All are expressed in the vomeronasal organ:
VN1Rs are expressed in the apical zone with the Gi G-protein subtype, and VN2Rs are
expressed in the basal zone with the G.. subtype. Both families probably signal through
phospholipase C (PLC) and inositol 1,4,5-triphosphate (IP3) via TRPC2 [56-60]. In
contrast, humans have only 5 potentially functional VN1Rs, and all VN2Rs are pseudogenes
[61]. When expressed in HeLa/Olf cells, all 5 human VN1Rs responded to volatile
molecules via Golf and cAMP [58]. The existence of a functional human vomeronasal organ
is questionable [62-70], but mRNA of one human VNR was detected in the main olfactory
epithelium, brain, lung, and kidney tissues [71]. This raises the possibility that human
VN1Rs may function more like ORs in the MOE, or may have non-olfactory functions.
1.1.6 Formyl Peptide Receptors
Formyl peptide receptors (FPRs) were originally discovered in the immune system.
Because these receptors recognized formylated peptides from bacteria or mitochondria, it
was widely believed that they functioned in recruiting phagocytes to sites of infection or
tissue damage [72].
Recent evidence suggests that this family of receptors may have an olfactory role
[15]. Five of seven mouse FPRs were selectively expressed in the mouse VNO [14, 15]. Like
VNRs, FPRs either co-expressed solely with G or G.., and can signal through PLC and IP3
[14, 15, 72]. As with the ORs, TAARs, and VNRs, only one gene was expressed by a neuron,
and no other chemosensory neurons were expressed. Although the location and
expression patterns of mouse FPRs indicate that they are chemosensory receptors, more
work needs to be done. However, it has been hypothesized that FPRs may aid in the
detection of predators or sick conspecifics, or may aid in the discrimination between
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members of the same species [14]. An olfactory role for the three human FPRs has not yet
been indicated.
1.1.7 Technological Motivations for Studying Olfaction
The mammalian olfactory system can instantly detect odorants at minute
concentrations and distinguish between them. Studies also indicate that smell can be used
to fingerprint individuals and detect cancer at early stages [73-76]. Although much is
known about morphology and signal transduction, the molecular basis of olfaction is not
understood. Ligands for the majority of the receptors are not yet known, and the role of
each of the four GPCR classes in olfaction has not been elucidated. If the mechanisms of
receptor-ligand interactions were understood, as well as the interactions between each of
the four systems, it might be possible to engineer highly sensitive and versatile detectors
for anything ranging from biological threats to terrorists to early stages of cancer.
1.2 Challenges in Membrane Protein Research
1.2.1 Overview
Despite their large numbers and biological importance, membrane protein research
lags far behind that of soluble proteins. Knowledge about GPCRs in particular is sparse.
This is due primarily to the difficulty of crystallizing membrane proteins, a precondition to
determining their structure. As of April 2011, over 72,000 protein structures have been
determined. Only 281 are unique membrane proteins (less than 0.4%!). Of these, only 6
are GPCRs (Table 1.1) [77, 78]. The first GPCR structure, that of rhodopsin, was solved in
2000. The second, the p2-adrenergic receptor, was solved seven years later. It was
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followed by two more in 2008: the p1-adrenergic receptor and the A2A-Adenosine receptor.
The last two, the CXCR4 chemokine and Dopamine D3 receptors, were crystallized in 2010.
GPCRs are difficult to crystallize for four main reasons. First, abundant quantities of
protein are needed to set up crystallization trials, but most are endogenously expressed at
low levels. Only rhodopsin, the first crystallized GPCR, is easily obtained in sufficient
quantities from native tissues. Second, suitable methods must be found to extract,
solubilize, and purify GPCRs. Third, GPCRs must be functionally stabilized for long periods
of time, as protein crystals can take weeks or even months to grow. Because GPCRs have a
hydrophobic transmembrane region bounded by hydrophilic ends, they aggregate and
precipitate out of aqueous solutions when removed from their native membrane
environment. Detergents that mimic the lipid bilayer chemistry must therefore be used to
maintain GPCRs in a stable, non-aggregated form. Fourth, the flexible nature of GPCRs, and
the materials used to stabilize them in aqueous environments, can inhibit crystal lattice
formation. Often, the GPCR to be crystallized must be cleverly engineered to increase
potential protein-protein contact sites. Each bottleneck must be sequentially overcome.
However, no universal method exists: optimal expression, purification, solubilization, and
engineering strategies must be empirically determined for each protein of interest.
Table 1.1: Protein Structure Statistics as of April 2011
Protein Type Total Number of Year of First Structure
Structures Determined
All proteins 72,717 1958
Membrane proteins 281 1985
GPCRs 6 2000
Olfactory-related GPCRs 0 n/a
1.2.2 Heterologous GPCR Expression
Systems capable of expressing GPCRs must be developed before any structural or
functional studies can be performed. This is a non-trivial task, as most GPCRs are expressed
at low levels in their native tissues, and are not easily amenable to expression in
heterologous systems. However, overexpression in heterologous systems can be
accomplished, and four main platforms have been developed towards this goal. It should
be noted that an expression methodology that works well with one protein may not yield
sufficient quantities of another.
1.2.2.1 Escherichia Coli Systems
Escherichia coli are an attractive receptor-expression platform because of their low
cost and fast doubling time (20-40 minutes). Plasmid DNA encoding the desired gene can
be synthesized quickly, and E. coli clones expressing the receptor of interest can easily be
generated. These characteristics allow expression of many GPCR variants to be tested and
optimized within a short span of time. However, E. coli expression systems suffer a number
of disadvantages. Often, the protein of interest must be fused to a bacterial leader
sequence to facilitate sufficient expression [79-82]. Because they are prokaryotic cells,
their intracellular environment is different from that found in eukaryotic cells. As a result,
overexpressed GPCRs can form inclusion bodies. While it is possible to isolate the
inclusion bodies, devising procedures to refold the proteins in an active state is a nontrivial
task. The reductive environment of the bacterial cytoplasm poses a particular challenge in
the functional expression and folding of GPCRs, as disulfide bridges necessary for proper
folding may not be able to form [81]. E. coli also lack the machinery capable of performing
post translational modifications like glycosylation. While this may yield a homogenous
protein sample, the synthesized receptors may be misfolded or non-functional. For
example, when the N-terminal glycosylation site of rhodopsin is blocked, the protein loses
its function [83, 84]. In ORs, loss of glycosylation may result in improper folding or loss of
function [85].
1.2.2.2 Yeast Systems
Yeast have been used as an expression system because they have short generation
times (2 hours), and are also inexpensive to use. Unlike E. coli, yeast are eukaryotes that
are capable of performing post-translational modifications like glycosylation [81, 82, 86,
87]. However, the composition of the N-glycans in yeast differs from that in mammalian
cells. Misfolded or non-functional proteins can result when a specific type and number of
carbohydrate chains must be added. Moreover, although yeast have the capability of
performing glycosylation, they often do not perform this modification on heterologously
expressed GPCRs. Additional difficulties that are often encountered include sequestering of
proteins in internal compartments, and proteolytic degradation of the synthesized
receptors. Lastly, the strength of the yeast cell wall can make purification of the expressed
receptors difficult [81, 82, 86].
1.2.2.3 Insect Cell Systems
Insect cells are eukaryotes capable of expressing high levels of functional GPCRs [81,
82]. Indeed all of the crystallized GPCRs except rhodopsin were expessed in Sf9 insect cells
[88-93]. As eukaryotes, they are capable of glycosylation. However, GPCRs can be poorly
glycosylated [94], or may not contain the appropriate sugars [95]. Additionally, incomplete
glycosylation results in heterogeneous protein samples, which are difficult to crystallize
[81, 82, 86]. Because some GPCRs either cannot be expressed in insect cells, or are non-
functional, an insect platform must be evaluated for each individual protein of interest.
Their long generation time (24 hours) makes this a time consuming process, and
evaluation of multiple GPCRs or variants of a single GPCR can be impractical.
1.2.2.4 Mammalian Cell Systems
Mammalian cells represent the most natural expression environment for most
GPCRs. They are closest to the tissues in which GPCRs are natively expressed, and are
capable of all necessary post-translational modifications. However, overexpression of
GPCRs can lead to incomplete or differential glycosylation, resulting in a heterogeneous
protein sample. Mammalian cells have the slowest doubling times (24-48 hours), are
prone to infection, and are expensive to handle. Overexpression of GPCRs in mammalian
cells is possible, but is usually toxic to the cells. Inducible stable cell lines can overcome
this problem [37, 96-99]. However, the process of creating a stable clone lasts several
months, and many potential clones must be screened to find a line that maximizes
expression, while minimizing toxicity or sources of heterogeneity (e.g. differential
glycosylation or degradation).
1.2.2.5 Cell-Free Systems
Cell-free protein expression offers a potential solution to the problems of low
yields, cell-toxicity, misfolding, protein heterogeneity, and receptor aggregation typical in
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cell-based platforms. In these systems, plasmid DNA encoding the protein of interest is
added to a mixture of amino acids and transcriptional and translational machinery directly
in a tube. Because the system is open, accessory reagents like lipids or detergents can be
easily added. Although cell-free expression is a mature technology for soluble proteins, it
has not been well established for membrane proteins. Several strategies have nevertheless
been developed for cell-free membrane protein synthesis.
The easiest method of expressing soluble membrane proteins is to add a detergent
directly to the synthesis reaction. However, the detergent must be carefully chosen, as it
can interfere with transcription or translation. Although numerous detergents must be
screened before an optimal one is found for a particular protein, mild non-ionic detergents
are usually preferred [100-103]. Because detergent micelles do not completely mimic the
mechanical and chemical properties of the lipid bilayer, solubilized proteins may not be in
their native conformation.
Because liposomes and membrane vesicles better mimic the lipid bilayer, several
studies have used them instead of detergents during cell-free expression. Two general
strategies have been employed. In the first, a membrane protein is expressed without a
surfactant. The resulting aggregate is purified and reconstituted in a liposome [104]. The
reconstitution step can also be performed with a mild detergent [104-107]. In the second,
liposomes or vesicles are added directly to the reaction. Membrane proteins are then
incorporated into them as they are expressed [108, 109]. Although liposomes and vesicles
can facilitate membrane protein expression, they are not a viable option for structural
studies due to the heterogeneity of the resulting samples. Liposomes have been reported to
range from 30-200 nm in diameter, and have varying numbers of incorporated proteins or
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no protein at all. Additionally, reconstitution conditions must be empirically determined
for each protein [104].
Nanolipoprotein particles (NLPs) have been developed to overcome some of the
shortcomings of liposomes and vesicles. NLPs are discoidal particles with a lipid bilayer
core surrounded by scaffold proteins [110]. Because the scaffold protein limits the size of
the disc, NLPs are relatively homogeneous in size (<5% deviation in mass). Also, NLPs
have been shown to enhance protein yields, achieving up to 0.9 mg/ml. They can be used
in cell-free extracts from multiple organisms, and are commercially available [111].
However, the usefulness of cell-free technology with GPCRs has yet to be reproducibly
demonstrated. Indeed, current cell-free methods typically either do not produce sufficient
GPCRs, or produce GPCRs that are inactive or misfolded [82, 104].
1.2.3 Detergent Selection for GPCR Solubilization
Because GPCRs have a hydrophobic core bounded by two hydrophilic surfaces,
detergents must be used to stabilize them once they are removed from their native
membrane environment. Selection of an appropriate detergent is critical, and is a difficult
and laborious task. These difficulties and the current state of the field are reviewed in
section 1.3.
1.2.4 Strategies for Facilitating GPCR Crystallization
Detergents used to solubilize membrane proteins form a protective belt, shielding
the hydrophobic transmembrane regions from the aqueous solution. This detergent belt
severely reduces the number of potential protein-protein contact sites, thereby reducing
the likelihood of crystal lattice formation. GPCRs present additional difficulties in
crystallization. A crystal is a well-ordered, repeating unit structure. The flexible nature of
of GPCRs can introduce heterogeneity that either reduces the resolution of any crystals or
inhibits their formation. In order to facilitate crystal growth, four general strategies for
increasing the hydrophilic surface area or increasing GPCR stability have been developed:
1) Monoclonal antibodies, 2) T4-Lysozyme insertions, 3) Stabilizing mutations or deletions,
and 4) Lipidic cubic phases.
1.2.4.1 Monoclonal Antibody Method
Monoclonal antibodies have been used to increase the polar surface area of
membrane proteins [112-115]. This strategy has been used successfully with several
membrane proteins, including one of the 6 crystallized GPCRs: the p2-adrenergic receptor
[91]. The advantages of using antibody fragments for crystallization are that they are
highly soluble, and can be engineered to bind with extremely high affinity to a protein of
interest. A relatively homogenous sample can be produced in E. coli, and it does not
destabilize the resulting antibody-membrane protein complex [116]. Although antibodies
can facilitate crystal-lattice formation, they suffer several drawbacks. The creation of a
high-affinity antibody requires considerable expertise and lasts at least several months.
Moreover, because they only bind to specific epitopes, non-stabilized portions of a protein
may be too flexible to be visualized [91].
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1.2.4.2 T4-Lysozyme Insertion Method
Insertion of T4-Lysozyme in the 3rd intracellular loop of GPCRs is an alternative
strategy that has been used to increase the polar surface area and potential number of
lattice-forming contacts [88-90,93]. T4-Lysozyme is a bacteriophage enzyme that is
soluble and easy to crystallize. The full protein has 164 amino acids and is about 18.6 kDa,
roughly half the size of olfactory-related GPCRs. Because it is highly soluble, it folds into a
distinct domain away from the transmembrane region (Figure 1.5). Four of the 6
crystallized GPCRs have used this strategy, which suggests that it could be used for
additional GPCRs. The ease of generating plasmid DNA templates and predicting
transmembrane regions makes this strategy more appealing than the use of antibodies.
Crystal structures of ligand-bound GPCRs indicate that the T4-Lysozyme insertion does not
significantly affect the transmembrane or binding pocket structure. However, because the
intracellular loops interact with G-proteins, the insertion likely disrupts signal transduction
[93].
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Figure 1.5. Crystal Structures of the p2-Adrenergic Receptor and Adenosine A2A Receptor
with T4 Lysozyme Fusions. A) The p2-adrenergic receptor is grey, and the T4 lysozyme fusion is
green. The transmembrane helices are numbered I-VII, and the second extracellular ioop is labeled
ECL2. From [88]. Reprinted with permission from AAAS. B) The adenosine A2A receptor is gold,
and the T4 lysozyme fusion is blue. The ioops, lipid bilayer boundaries, and ligand are labeled.
From [90]. Reprinted with permission from AAAS. The T4 lysozyme domain folds away from the
native protein, thereby minimally disturbing the structure of the transmembrane regions.
1.2.4.3 Targeted Mutation Methods
Targeted mutations have been introduced in order to sufficiently stabilize GPCRs for
crystallization. The intent of such mutations is to stabilize the receptor's structure, or to
facilitate formation of a well-ordered crystal. The most common mutation is a deletion of
large and flexible loop or terminal regions [88-92]. Point mutations that confer thermal
stability [89, 92, 93] or that remove palmitoylation sites [92] have also been performed.
Experiments indicate that these mutations do not significantly alter receptor structure or
binding.
1.2.4.4 Lipidic Cubic Phase Method
Lipidic cubic phases (LCPs) are hypothesized to facilitate crystallization by
mimicking the cell-membrane better than detergent micelles [116]. LCPs are bicontinuous
nanoscale structures formed between lipids and an aqueous solution. Because of their
immiscible nature, the lipids pack together to form a continuous bilayer that separates 2
distinct but interpenetrating aqueous phases (Figure 1.6). Diffusion coefficients in the lipid
bilayer are similar to those in cell membranes, and diffusion in the aqueous compartments
is comparable to that in bulk water [116, 117]. Membrane proteins incorporated into the
LCP network can freely diffuse in the lipid layer, while soluble additives can diffuse in the
aqueous compartments. This structure allows lattice-forming contacts to be made with
both hydrophilic and hydrophobic protein regions. Moreover, the planar nature of the lipid
bilayer allows it to exert mechanical stresses comparable to those in the cell membrane,
thereby maintaining protein structure more efficiently than detergent micelles [88, 116,
118]. Four GPCRs have been crystallized using LCPs [88-90, 93], indicating their efficacy.
However, LCPs still suffer similar drawbacks as traditional crystallization methods. The
number of parameters that must be tested is large, and include protein concentration, lipid
content, detergent type, salts, temperature, and pH. Optimal crystallization conditions
must be empirically determined for each tested protein. Also, a protein must be solubilized
in detergent before it can be incorporated into an LCP matrix. But, high detergent
concentrations can cause the cubic phase to become lamellar [116], which is not conducive
to crystal formation.
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Figure 1.6. Lipidic Cubic Phases for Protein Crystallization. A) Detergent-solubilized protein
(top) is added to a lipidic cubic phase (bottom). B) The protein is incorporated into the LCP. C)
Salts or precipitants are added to facilitate crystal nucleation and growth. D) As the water content
decreases upon the addition of salt, the bilayer curvature increases. The proteins are free to diffuse
in the bilayer, and can form lattice-forming contacts. Reprinted from [117], with permission from
Elsevier.
1.3 Detergents for Use with Membrane Proteins
1.3.1 Overview
Membrane proteins have evolved to stably exist in biological membranes, which are
fluid, amphipathic, and anisotropic structures. To maintain this stable integration,
membrane proteins are comprised of a hydrophobic core embedded within the lipid
bilayer, and hydrophilic ends that remain in the polar portion of the bilayer or extend into
the extracellular or cytosolic space. As a result, they are not soluble in either completely
polar or completely hydrophobic solvents. Amphipathic molecules that mimic the
properties of biological membranes must be used to handle this class of proteins outside
their native environment.
1.3.2 Detergent Properties
In aqueous solution, detergent molecules exist as monomers that can transition to
two basic phases [119]. One phase is crystallization, though this does not typically occur
with detergents used for membrane proteins. The second phase is micellarization. At a
concentration above a critical value, detergent monomers self-aggregate into spherical
micelles where the non-polar tails are sequestered in the center and the polar head groups
interface with the aqueous solvent. This concentration is denoted the critical micelle
concentration (CMC). Detergent solutions at or above their CMC are capable of solubilizing
membrane proteins: the detergent micells are able to encapsulate the hydrophobic protein
core and substitute for the plasma membrane. At significantly high concentrations,
detergents are able to disrupt cellular membranes and extract membrane proteins.
The size and shape of detergent micelles depends on the properties and chemistry
of the monomer head and tail groups, as well as the temperature, pH, ionic strength, and
general nature of the solvent. The head group typically affects the CMC and average
number of monomers in a micelle. As a general rule, in a series of detergents with the same
head group, the CMC decreases by a factor of 10 for every 2 methylenes added to an alkyl
tail. Shorter chain detergents tend to have higher CMC values, while longer chain
detergents can be less soluble, thereby having lower CMC values. Detergent families with
larger or more soluble headgroups are more soluble (Table 1.2) [120, 121]. In general,
detergents with shorter chain lengths, smaller head groups, and charged head groups are
harsh and can lead to protein denaturation or instability. However, they can be better at
extracting proteins from the lipid bilayer or crystallizing membrane proteins. Detergents
with longer alkyl tails, larger head groups, or head groups with a neutral charge are milder,
and are better able to stabilize membrane proteins [120]. Detergent monomers in a
micelle are in equilibrium with the free monomers in the solvent. This property allows one
detergent to be exchanged for another. Because detergents with longer alkyl chains
typically have a slower rate of exchange, only detergents with a lower CMC or smaller
micelle size can be replaced.
Table 1.2: D etergent Properties
Detergent Formula Structure CMC* Aggregation Solubility*
(mM) Number*
N-octyl-p-D C14 H2 8 0 6  HH 18-20 27-100 >20%
glucopyranoside HO H0 (0-5-C)
N-decyl-s-D- C16H 3 2 0 6  HO40 2.2 NA >0.1%
glucopyranoside H O (20'C)
N-dodecyl-p-D- C1 8H36 0 6  HOHO 0.19 NA >0.008%
glucopyranoside (20*C)
N-octyl-p-D- C2 0H38 0 1 1  HO 19.5** 6 >20%
HO
maltopyranoside H OH H (0-5"C)
N-decyl-p-D- C22H42011 HO 1.8 45 >20%
maltopyranoside H H (0-5"C)
OH O
N-dodecyl-p-D- C24 H46011  H0.17 78-149 >20%
maltopyranoside H H (0-5"C)
* All CMC, aggretation number, and solubility values were determined in water unless otherwise specified.
** Water with 100mM NaCl, 20mM HEPES, pH 7.5
Data was obtained from Anatrace's online product information [121]
1.3.3 Detergent Classes
Chemical detergents are amphipathic molecules that have traditionally been used to
solubilize, stabilize, and crystallize membrane proteins. Three general categories of
detergents have been used: ionic, nonionic, and zwitterionic. Ionic detergents are typically
harsh, and can often completely denature proteins or dissociate complex proteins into their
constitutive components. The ionic strength and nature of the counterion in solution also
affect ionic detergent properties; charge-shielding effects can diminish repulsion between
the charged head groups and lead to a lower CMC and larger average micelle size.
Temperature and pH are also important factors. Particularly, such surfactants can only
solubilize proteins at a pH above (for anionic) or below (for cationic) the pKa of the
ionizable head group. Because of these variables, it is necessary to demonstrate that native
protein function is maintained under experimental conditions when using ionic detergents.
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Zwitterionic detergents have an overall electrically neutral charge, and do not suffer from
the same drawbacks as ionic detergents. They are better able to protect the native state of
the membrane protein, and are used more often than ionic detergents to solubilize and
stabilize them. Nonionic detergents, particularly those with polyoxyethylene or sugar head
groups, are perhaps the gentlest class of detergents. Because they are strong enough to
disrupt lipid-lipid or lipid-protein interactions, but not protein-protein interactions, they
are used most often to solubilize and stabilize membrane proteins, and to study their
functions. This class of detergents has also been most successfully used to crystallize
membrane proteins. Indeed, nearly 40% of membrane protein structures have been
determined with the nonionic detergents LDAO (N,N-dimethyldodecylamine-N-oxide),
DDM (N-dodecyl-p-D-maltopyranoside), and OG (N-octyl-p-D-glucopyranoside) [122, 123].
1.3.4 The Protein Detergent Complex (PDC)
Solubilized membrane proteins must exist in a complex bound with detergent This
complex (PDC) has properties different from either the protein or detergent micelle alone,
which must be considered during crystallization experiments.
Detergents bind to membrane proteins in a torus-like shape, shielding the
hydrophobic core from the aqueous solution [124,125]. The detergent, protein, and
solvent properties affect the average size and shape of this detergent "belt". However,
micelle packing is not perfectly spherical, as is usually assumed and illustrated. Molecular
dynamics simulations indicate that the detergent tails pack in a more compact and
disordered configuration (Figure 1.7). As a result, the micelle surface is rough and
heterogeneous, and portions of the hydrophobic tails can have significant contact with the
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surrounding solution [119]. The degree of contact between the tails and solution can
influence protein aggregation; if a detergent is not able to sufficiently shield the
transmembrane portions of a protein, these regions may self-aggregate and precipitate out
of solution. Typically, this aggregation is irreversible [120].
A B C
Figure 1.7. Detergent Micelle Models. A) The classical spherical micelle model. B) A 20-
monomer micelle model after a 40ns molecular dynamics simulation C) A 50-monomer micelle
model after a 40ns molecular dynamics simulation. The polar oxygens are colored red; the
hydrophobic carbon tails are grey. Contrary to simple classical illustrations, portions of the
hydrophobic micelle core are exposed to the solvent. This research was originally published in
[119]. @The American Society for Biochemistry and Molecular Biology.
The molecular weight of the PDC can be twice that of the native protein, or more.
The number of detergent molecules bound to the protein depends not only on the
detergent aggregation number and protein size, but also on the detergent concentration.
For example, at 103mM, about 40 molecules of OG were bound to prostaglandin H
synthase-I (PGHS-I). At 23.9mM, the number of bound OG molecules was almost double.
. ......... ....... . . .... .. .... .  .....
Because the protein-bound detergent will form most of the non-solvent mass in a protein
crystal, its properties can often dominate over those of the protein. Thus, the detergent
properties need to be carefully considered, in tandem with the protein properties, when
setting up crystallization screens [120,124].
1.3.5 Current Problems with Traditional Detergents
Many problems exist with current detergent-membrane protein protocols. First, a
bewilderingly wide range of detergents is available. Yet, no single detergent or class of
detergents is universally useful for any given experiment or family of proteins. For
example, although LDAO is one of the most successfully used detergents in crystal screens,
it is estimated that only 20% of membrane proteins are soluble and stable in it [126]. The
optimal detergent for a given protein must therefore be determined empirically. The
optimal concentration must also be tested, as low concentrations may not sufficiently
solubilize the protein and high concentrations could denature it. Second, the detergent that
works best for one application may not work at all in another. For example, detergents
with smaller micelles can increase protein solubility and the number of potential protein-
protein lattice-forming contacts, but also lead to protein denaturation or instability. Thus,
while perhaps aiding in protein solubilization and crystal formation, a detergent could
adversely affect the protein's structure or function. An additional confounding factor is
that the order of surfactant use can be a critical concern. For example, PGHS crystals that
were grown in OG were of better quality if the protein was first solubilized in ClOM instead
of Tween-20 before exchanging surfactants [124]. Third, surfactants can exhibit complex
phase behavior under specific environmental conditions (i.e. temperature or
concentration). This behavior can affect the experimental outcome or state of the
solubilized protein.
1.3.6 Novel Amphiphile Systems for Membrane Protein Solubilization
Because detergents play a crucial role in membrane protein experiments, and
because it is difficult to find the "perfect detergent", research efforts have focused on
developing new amphiphilic systems. The primary goal is to develop a more universal
surfactant that can both maintain protein stability and facilitate crystallization.
Several novel surfactant systems have been developed. The first novel non-
detergent surfactant was designed in 1993 [127]. It was comprised of a 24-amino acid
peptide that folded into an alpha-helix with a hydrophilic face and a hydrophobic face. The
peptide monomers assembled into an anti-parallel four-helix bundle. This bundle was able
to maintain 85% of a bacteriorhodopsin sample and 60% of a rhodopsin sample soluble for
2 days. However, it was unable to solubilize PhoE porin. A lipopetide detergent (LPD) that
used the same basic framework was designed to improve protein stability, and address the
problem of imperfect micelle packing [126]. This surfactant was comprised of an alpha
helix that had fatty acids coupled to each end. LPD monomers formed a wedge-like shape,
and assembled into a cylindrical structure with the fatty acid chains sequestered in the
core. LPDs with fatty acid chains of various lengths were able to solubilize
bacteriorhodopsin, lactose (lac) permease, PagP, and a beta barrel protein. They were also
able to maintain the stability of solubilized bacteriorhodopsin and lac permease over one
month at room temperature. Although LPDs may offer many advantages over traditional
detergents, they are significantly more expensive to synthesize and purify. It is not
practical to use LPDs during any of the protein purification steps, and it may not even be
economically feasible to produce enough material to set up the numerous screens
necessary for crystallization experiments [126]. Other developed systems include tripod
amphiphiles, and surfactant polymers or amphipols [128-131].
1.3.7 Problems with Novel Surfactant Strategies
Although several novel surfactant systems have been developed and tested, none is
ideal. The bio-surfactants are expensive to obtain at high purity, and require proper
folding before they become useful. The chemical surfactants can require extensive
screening or yield heterogeneous populations that may interfere with crystal growth.
Furthermore, most have only been tested on rhodopsin or bacteriorhodopsin. These
proteins are easy to obtain or express in large quantities, and their handling, working, and
crystallization conditions are well known. Of the handful of other proteins tested, none are
GPCRs, and all are membrane proteins that have known experimental working conditions.
Success with these "easy to handle" membrane proteins does not imply success with more
difficult proteins, even of the same family. Limited testing of these surfactants also does
not demonstrate their general use as a class among a broad range of proteins. Economical
de novo surfactants capable of solubilizing and stabilizing membrane proteins that are
more difficult to express or handle are needed.
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CHAPTER 2
LARGE-SCALE EXPRESSION OF
hVN1R1 IN A STABLE HEK293 CELL
LINE
This chapter is an expansion of a manuscript submitted to Scientific Reports:
Corin, K., Baaske, P., Geissler S., Wienken C.J., M., Duhr, S., Braun, D. & Zhang, S.
(2011) Biochemical study of a bioengineered functional G-protein coupled receptor:
the human vomeronasal type 1 receptor 1. Scientific Reports (submitted).
2.1 Introduction
2.1.1 HEK293 Cells as a GPCR Expression Platform
Large-scale expression of GPCRs is necessary before structural or functional studies
can be performed. However, this presents a daunting task. GPCRs are endogenously
expressed at low levels, and high levels of expression in heterologous systems typically
result in cell toxicity, protein misfolding, or aggregation.
Mammalian cells are arguably the most ideal cells in which to express GPCRs, as the
environment they provide is closest to the native environment of most GPCRs. They also
have the necessary machinery to perform glycosylation and other post-translational
modifications. However, yields are typically low, and decrease with each cell passage after
transient transfections. Moreover, the expressed proteins can be in various stages of
expression or degradation. Such an inhomogeneous sample can inhibit crystallization, and
may also interfere with other assays.
Large-scale expression of rhodopsin and an olfactory receptor in HEK293 cells has
previously been reported [1-3]. The authors were able to generate stable inducible cell
lines that yielded milligram quantities of homogenous receptors. They were also able to
purify the proteins using size exclusion chromatography alone, and show that the purified
protein was properly folded and functional. However, the expressed proteins retained
their glycosylation sites, and were glycosylated [2]. In order for purified protein to be
useful for crystallization screens, the carbohydrate chains must be removed without
altering the receptors' structure or function.
Success with two receptors suggests that HEK293 cells may be able to produce
additional GPCRs. Little information is available on human vomeronasal receptors. This is
partly due to the ambiguity of whether humans have a functional vomeronasal organ, and
partly due to the difficulty of expressing these receptors. A human vomeronasal receptor is
thus an attractive candidate for expression in HEK293 cells.
2.1.2 The Human Vomeronasal Organ and Receptors
Although the existence and function of a human vomeronasal organ (VNO) is
controversial, almost all studies agree that a vomeronasal organ is present in the
developing fetus. However, many studies report that this organ is vestigial, and function is
lost in adults, while others report development of a mature organ [4-9]. Interestingly, one
study found that the ability to detect the adult VNO can vary; the investigators could not
find VNOs in subjects that had clearly identifiable organs on prior inspections, and vice
versa [4].
In most mammals, signals from the VNO are directed to the accessory olfactory bulb
(AOB). However, studies in humans suggest that degenerative changes occur in the fetal
AOB, and that it isn't present in adults [7, 8]. Most studies that used neuron-specific stains
failed to find evidence of nerve bundles [4, 9]. Others suggest the presence of neurons in
the adult vomeronasal organ, albeit at a low density [10]. In spite of this, some studies
indicate pheromonal responses in humans directly through the VNO. Androstadionone
applied directly to the female VNO decreased nervousness, tension, and negative feeling
states. Decreases in cardiac frequency and respiratory frequency, and increases in body
temperature and alpha-cortical activity, were also measured [11]. When a steroidal
vomeropherin was applied to the male VNO, a decrease in follicle-stimulating hormone and
luteinizing hormone pulsatility was observed. Changes in cardiac frequency, respiratory
frequency, and other physiological responses were also observed [12].
Taken together, current evidence suggests that humans may have a functional
vomeronasal organ that functions differently than in other mammals. However, until
recently, it was believed that human vomeronasal receptors (VNRs) were all pseudogenes.
In 2002, Rodriguez and Mombaerts found 5 VNR type 1 (VN1R) genes with open reading
frames. They were successfully expressed in HeLa/Olf cells [14]. Interestingly, all five
were found to respond to volatile molecules and signal through the canonical olfactory
signaling pathway. Even more curiously, mRNA of one receptor - hVN1R1 - was detected
in several other tissues, including the main olfactory epithelium (MOE), brain, lung, and
kidney [15]. This raises the possibility that human VN1Rs may function more like
olfactory receptors in the MOE, or may have non-olfactory functions.
Studying human vomeronasal receptors at the molecular level may shed light on
both their function and that of the human vomeronasal organ. However, the difficulty of
functionally expressing and purifying these G protein-coupled receptors in sufficient
quantities is a major obstacle towards research. Only one report has produced functional
receptors in cells, and identified potential ligands [14]. However, in order to study their
structure and function, it is necessary to produce and purify milligram-scale quantities.
This study shows that it is possible to generate a stable, inducible HEK293 cell line capable
of expressing milligram quantities of the human vomeronasal receptor hVN1R1. A novel
finding is that removal of glycosylation sites does not impede membrane localization of the
expressed receptors. Circular dichroism indicated that the purified receptor was properly
folded with stable a-helical domains. Microscale thermophoresis showed that the purified
receptor was able to bind its reported ligand. These results provide the basis for carrying
out further structural analyses of human vomeronasal receptors, and enable screens for
crystallization trials. They could also aid in future studies aimed at identifying the
biological role of human VNRs.
2.2 Methods
2.2.1 hVN1R1 Gene Design and Construction
The protein sequence for hVN1R1 was obtained from GenBank (AAG10698). To
enable expression and purification from mammalian cells, the following modifications were
made: 1) addition of a C-terminal rho tag (TETSQVAPA) preceded by a two glycine linker;
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2) human codon optimization; 3) addition of a Kozak sequence 5' to the start codon; 4)
addition of a 5' EcoRi site and a 3' Xhol site to facilitate subcloning into expression vectors;
5) addition of an N-terminal strep tag (ASWSHPQFEK) followed by a GSSG linker for further
purification; and 6) N117Q, N151Q, N183Q, N198Q, and N256Q mutations to facilitate
crystallization. The genes were constructed by Geneart and ligated into the pcDNA 4/To
vector (Invitrogen, Carlsbad, CA). The plasmid was amplified in subcloning efficiency
DH5a E. coli (Invitrogen) and purified using MiniPrep or MaxiPrep kits (Quiagen, Valencia,
CA). The transmembrane and loop domains were predicted using the TMHMM Server v 2.0
(http://www.cbs.dtu.dk/services/TMHMM/). N-linked glycosylation sites were predicted
using the NetNGlyc 1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/).
2.2.2 Construction of Stable Inducible hVN1R1 HEK293G Cell Lines
HEK293S N-acetylglucosaminyltransferase I-negative cells (HEK293G) containing
the pcDNA6/Tr vector [2] were transfected with the pcDNA4/To hVN1R1 vector using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. Forty-eight
hours after transfection, selective media containing 5gg/ml of blasticidin and 50pg/ml
zeocin was added. Cells were re-seeded at low density and grown until individual colonies
formed. Forty-eight colonies were picked and screened for inducible hVN1R1 expression.
Cells were treated with plain media, media supplemented with 1pg/ml tetracycline, and
media supplemented with 1ig/ml tetracycline and 2.5mM sodium butyrate. Two days
after induction, cells were scrape-harvested and solubilized in PBS with 2% w/v Fos-
Choline 14 (FC-14) (Anatrace) and protease inhibitors (Roche #04693132001) for 1 hr at
4"C. Cell lysates were centrifuged for 30 minutes at 10,000 rpm to remove insoluble debris.
Dot blots and Western-blotting were used to compare protein expression among clones.
The clone with the highest expression when induced, the least detectable expression when
not induced, and least toxicity upon induction, was expanded for future experiments. All
cultures were grown in DMEM F12 with GlutaMAX (Invitrogen #10565-042) supplemented
with 10% fetal bovine serum (Invitrogen #16000-044), 15mM HEPES (Invitrogen), 0.1mM
non-essential amino acids (Invitrogen), 0.5mM sodium pyruvate (Invitrogen), 10OUnits/ml
penicillin and 100ig/ml streptomycin (Invitrogen). The expanded stable hVN1R1 clone
was maintained in media that also contained 5 [g/ml blasticidin and 25[ig/ml zeocin. All
cells were grown at 37"C, 5% C02, and 95% relative humidity.
2.2.3 Immunocytochemistry
Vomeronasal receptors were visualized using a rholD4 primary antibody. Cells
were seeded at low density on poly-L-lysine (Sigma-Aldrich) coated glass coverslips. After
one day, cells were induced with 1ptg/ml tetracycline and 1mM sodium butyrate. One day
after induction, the media was removed. Cells were gently washed with PBS and fixed for
20 minutes in 10% neutral buffered formalin (Sigma-Aldrich) at room temperature.
Permeabilized (1:1 acetone:methanol, 3 minutes, -20'C) and non-permeabilized cells were
then blocked in PBST (PBS, 0.2% tween-20, 0.3M glycine, 4% serum) for 1 hour at room
temperature, and incubated with the primary antibody solution (1:1000, PBS, 0.2% tween-
20, 4% serum) overnight at 4*C. The labeled protein was visualized with Alexa-flour-488
goat-anti-mouse secondary antibody conjugate (1:3000, PBS, 1 hour, room temperature).
Slides were mounted using ProLong Gold Antifade with DAPI.
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2.2.4 Cell Extract Preparation
Cells were grown on plates as previously described [2]. When the appropriate
density was reached, cells were induced with lg/ml tetracycline and 2.5mM sodium
butyrate. Two days after induction, cells were scrape harvested, pooled, snap frozen in
liquid nitrogen, and stored at -80"C until used for future experiments.
2.2.5 Detergent Screening
Frozen cell pellets were thawed on ice and resuspended in PBS containing protease
inhibitors (Roche). Detergents were added to a final concentration of 2% w/v. The
suspensions were rotated for 1 hour at 4"C to solubilize the protein, and were spun at
13,000 rpm for 30 minutes to remove insoluble fractions. Relative protein solubilization in
each detergent was assayed with a dot blot. Ninety-six detergents were selected for
screening as previously described [16].
2.2.6 Receptor Purification
RholD4 immunoaffinity purification has been previously described [2, 3]. Briefly,
frozen cell pellets were thawed on ice. Cells were resuspended in PBS containing protease
inhibitors. PBS containing FC-14 was added to a final concentration of 2% w/v FC-14. The
final liquid:cell ratio was 12.5ml/lg cells. The protein was solubilized by rotating for 4
hours at 4'C. The non-solubilized fraction was pelleted by centrifuging for 30 minutes at
30,000g at 4"C. The solubilized fraction was incubated with DNAse (1:2000) and RNAse
(1:1000) for 15 minutes on ice. RholD4-coupled CNBr-activated Sepharose 4B beads (GE
Healthcare) were added to the cell extract supernatant (binding capacity 0.7mg/ml);
receptors were captured by rotating the mixture overnight at 4"C. The beads were
collected by centrifuging at 1400 rpm for 1 minute, or filtering the supernatant through a
filter column (Biorad). The supernatant was saved for future analysis and labeled as "flow-
through". The beads were resuspended in 1 bead volume of wash buffer (PBS + 0.2% w/v
FC-14), rotated for 10 minutes at 4"C, and re-pelleted. Washes were performed until the
total protein concentration in the washes was less than 0.01mg/ml (NanoDrop). One bead
volume of elution buffer (PBS+0.2% w/v FC-14 + 800uM Ac-TETSQVAPA-NH 2 peptide) was
then added to the beads. Elutions were performed until the total protein concentration
was less than 0.01mg/ml.
Size exclusion chromatography was used to separate the monomeric and higher
molecular-weight forms of the receptor. A Hi-Load 16/60 Supradex 200 column with an
Akta Purifier HPLC system (GE Healthcare) was used. The column was first equilibrated
with at least 1 column volume of wash buffer. Protein samples were concentrated to 1.5-
3ml using a 50,000 MWCO filter column (Millipore), loaded on the column, and run with
wash buffer at 0.3ml/min. Fractions exiting the column were automatically collected;
protein content was monitored with UV absorbance at 215nm, 254nm, and 280nm. Peak
fractions were pooled, concentrated, and analyzed with Western blotting and silver
staining (SilverXpress, Invitrogen).
2.2.7 Secondary Structure Analysis Using Circular Dichroism Spectroscopy
CD spectra were measured over the wavelengths 200nm-350nm with a CD
spectrometer (AVIV Biomedical Model 202). Measurements were made at 15"C, with a step
size of 1nm and an averaging time of 4 seconds. Measurements for each sample were made
in triplicate and averaged. Protein samples were concentrated to at least 0.1mg/ml for far
UV readings, and 1.7mg/ml for near UV readings; concentrations were determined by
averaging ten spectroscopic measurements (Nanodrop). The protein spectra were blanked
to the spectrum obtained for wash buffer. A QS quartz cuvette (Hellma) with a 1mm path
length was used to perform all experiments.
2.2.8 Ligand Binding Measurements Using Microscale Thermophoresis
Thermophoresis was used to measure the binding interactions between purified
receptors and their ligands using a setup similar to that previously described [17, 18]. To
eliminate artifacts caused by labeling or modifying proteins, the fluorescence of native
GPCR tryptophans was used to monitor the local receptor concentration. For each sample,
a titration series with constant receptor concentration and varying ligand concentrations
was prepared in a final solution of 10% DMSO and 0.2% FC-14 in PBS. Potential
autofluorescence of each ligand was checked: no fluorescence signal was detected from the
ligands in the tryptophan fluorescence channel. The final receptor concentration was 1-
2 [M. Approximately 1.5 Id of each sample was loaded in a fused silica capillary (Polymicro
Technologies, Phoenix, USA) with an inner diameter of 300 m. An infrared laser diode was
used to create a 0.12K/pm temperature gradient inside the capillaries (Furukawa
FOL1405-RTV-617-1480, wavelength A=1480nm, 320mW maximum power, AMS
Technologies AG, Munich Germany). Tryptophan fluorescence was excited with a UV-LED
(285nm), and was measured with a 40x SUPRASIL synthetic quartz substrate microscope
objective, numerical aperture 0.8 (Partec, Goerlitz, Germany). The local receptor
concentration in response to the temperature gradient was detected with a photon counter
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PMT P10PC (Electron Tubes Inc, Rockaway, NJ, USA). All measurements were performed at
room temperature. Fluorescence filters for tryptophan (F36-300) were purchased from
AHF-Analysentechnik (Tubingen, Germany).
2.3 Results
2.3.1 Induction of hVN1R1 Expression in a Stable HEK293 Cell Line
Producing milligram quantities of homogenous membrane protein samples is
notoriously difficult. Over-expression of these proteins in mammalian cells is often
reported to have toxic effects, which reduce the total protein yield. Additionally,
constitutive expression of such proteins yields non-homogeneous samples, as proteins can
be in various stages of synthesis, degradation, or post-translational modification. To
minimize toxic effects, and to generate a homogenous protein sample, the Invitrogen T-REx
system was used to create stable hVN1R1- inducible cell lines [2]. This system allows large
batches of cells to be grown and simultaneously induced to express protein.
Sodium butyrate has previously been used to enhance tetracycline-regulated
protein expression [1, 2]. Induction of VN1R1 expression was thus tested with tetracycline
alone, and tetracycline combined with sodium butyrate at various concentrations. No
detectable protein expression was seen in the absence of induction agents. Sodium
butyrate combined with tetracycline enhanced protein expression 4-5 fold over induction
with tetracycline alone. Significant cell death was observed in cultures treated with both
tetracycline and sodium butyrate, indicating the toxic effects of protein expression. The
clone with the highest expression, the least toxicity, and least degradation products was
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selected and expanded. For all subsequent experiments, the following induction condition
was used: 1 [ig/ml of tetracycline and 2.5 mM of sodium butyrate for 48 hours.
SDS-PAGE and Western blotting analysis were used to characterize the protein
samples. Immunoblotting against the rholD4 tag revealed two bands, which correspond in
size to monomeric and dimeric forms of the receptors. This size pattern has been reported
for several olfactory receptors [2, 19, 20], and is the first such reporting for a human
vomeronasal receptor. The hVN1R1 sample also showed evidence of a degradation
product.
2.3.2 Immunohistochemical Staining of Induced Cells
Numerous studies report the difficulty of expressing GPCRs in heterologous
systems, and particularly of targeting proteins to the membrane [21-24]. Glycosylation,
particularly of specific conserved N-terminal sites, may be necessary for proper protein
folding and localization [25]. However, glycosylation can lead to inhomogenous samples
and make crystal packing difficult. Here, the native protein was used with potential
glycosylation sites removed. To determine whether removal of predicted glycosylation
sites affected protein localization, induced cells were stained with antibodies against the
rholD4 tag. (Figure 2.1) Non-induced cells showed negligible fluorescence.
Permeabilized cells stained with the rho1D4 tag demonstrated membrane-localization of
both proteins. These results indicate that the protein is trafficked to the cell membrane.
They further demonstrate that the hVN1R1 glycosylation sites are not necessary for
membrane localization in HEK293 cells, and indicate that they are not necessary for
appropriate protein folding.
Figure 2.1. Immunohistochemical Staining of HEK293 Cells Expressing hVN1R1. A) Non-
induced HEK293 cells show no staining. B) Induced HEK293 cells stained with the rholD4
antibody show that the expressed hVN1R1 is localized to the cell membrane.
2.3.3 Systematic Detergent Screening for Receptor Solubilization
Selection of an appropriate detergent is critical for the successful solubilization of a
GPCR from a cell membrane, and for the subsequent purification and stabilization of the
receptor. Since the optimal detergent can vary even between proteins in the same family, it
must be empirically determined. Thus, a systematic detergent screen was performed
(Figure 2.2).
Ninety-six detergents were screened. These detergents belonged to one of four
general classes: anionic, cationic, non-ionic, and zwitterionic. The detergents were chosen
from a commercial Solution Master Detergent Kit [16], and included detergents that have
been successfully used to purify, solubilize, or crystallize GPCRs. Additionally, several
. ........ ............... ............ __ ' -, - _ _._ =I: !I!
detergent mixtures were tested as previously described [16]. All detergents were used at a
concentration of 2%, which was above the critical micelle concentration, with the exception
of MEGA-8.
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Figure 2.2. Detergent Screens for Solubilizing hVN1R1 from HEK293 Cells. HEK293 cells were
induced with tetracycline and sodium butyrate for 48 hours. The cells were then scrape-harvested
and incubated with the shown detergents in order to disrupt the membrane and extract the
expressed protein. A dot blot was used to compare the relative amounts of solubilized receptor.
Zwitterionic detergents typically solubilized a greater portion of the expressed protein, though
several cationic and anionic detergents were able to solubilize significant amounts. The fos-choline
detergents were the sub-class of detergents that solubilized the greatest amount of protein. The
names corresponding to the detergent numbers are listed in Chapter 3.
The most effective detergents for hVN1R1 solubilization were the zwitterionic fos-
choline series (#71-78) and n-Dodecyl p-iminodpropionic acid (DIPA, #89). The
zwitterionic cyclofos-7, cationic hexadecyl- and tetradecyltrimethylammonium chloride
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detergents (#8, 9), and anionic sodium dodecanoyl sarcosine (#5) were also reasonably
effective, while most other detergents failed to solubilize a significant amount of receptor.
Similar results with other GPCRs have previously been reported [3, 16]. The effectiveness
of the fos-choline (FC) series to solubilize membrane proteins is not surprising: they are
structurally related to phosphatidylcholine, a constituent of the phospholipid bilayer.
Although FC15, FC16, and DIPA were able to solubilize more protein, FC14 was chosen for
all subsequent experiments: The CMC for DIPA has not been established, and FC15 and
FC16 have much lower CMCs, which could inhibit detergent substitution in downstream
experiments. Furthermore, previous experiments indicate that the fos-choline family may
promote proper folding as well as stabilize the protein structure [26]. Additionally, FC14
has been used for membrane protein solubilization and purification [2, 3, 16, 27], and has
been used to crystallize and solve two high-resolution protein structures [28, 29].
Because the optimal detergent for a given membrane protein must currently be
determined empirically, finding a detergent that can stabilize a class of membrane proteins
would be an important contribution. This would save time and resources, and also shorten
the path towards studying more membrane proteins. These results contribute to a growing
body of evidence that FC14 is a promising detergent for solubilizing diverse GPCRs from
cells, and stabilizing the receptors. In addition to hVN1R1, it has solubilized and stabilized
various other GPCRs, including several chemokine receptors (CCR3, CCR5, CXCR4,
CX3CR1), several olfactory receptors, and the trace-amine associated receptor 5 [2, 16, 27,
30]. FC14 thus seems like a promising choice in membrane protein studies, and
particularly in crystallization trials.
2.3.4 Purification of HEK293 -Expressed hVN1R1
A two-step process using immunoaffinity chromatography and size-exclusion
chromatography (SEC) was used to purify the expressed hVN1R1 receptors (Figure 2.3)
[2, 3].
A small-scale purification was performed to determine the potential of using
heterologous expression for large-scale protein production. Solubilized protein was first
bound to rholD4-tagged Sepharose 4B beads. After thoroughly washing the column to
remove impurities, the protein was eluted with an excess of the rholD4 epitope peptide
Ac-TETSQVAPA-NH2. To further purify the protein, remove the elution peptide, and
separate the monomeric and dimeric forms, the receptor sample was subjected to SEC. The
column flow through was monitored with UV absorption at 280 nm and 215 nm, and was
automatically collected in separate fractions. The UV spectrum showed 4 distinct peaks
(Figure 2.3A). The fractions corresponding to these peaks were pooled, concentrated, and
analyzed with western blotting and silver staining. As seen in Figure 2.3B, peaks 3 and 4
correspond to the monomeric form, which could be obtained at >90% purity. Earlier peaks
primarily corresponded to dimerized and aggregated protein, though the monomeric form
was present throughout. Western blotting and total protein stains demonstrated that all of
the expressed receptor had been captured by the beads. One gram of cells yielded
approximately 1 mg of total protein. Of the protein recovered after SEC, up to 66% was
the monomer. These yields are sufficient to obtain large quantities of highly pure receptor
for biochemical and analyses and crystal screens. Bioreactor suspension cultures could
also potentially be used to increase the protein yield [3].
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Figure 2.3. Purification of hVN1R1. A) 280nm UV trace of hVN1R1 through a size exclusion
column (SEC). Four distinct peaks were observed. The fractions corresponding to the peaks were
pooled and run on a gel. B) Silver stain of the SEC fractions shown in A). The first peak in A)
primarily corresponded to higher molecular weight aggregates. The second peak contained
dimerized receptor. The third and fourth peaks contained a monomeric version of hVN1R1. This
form of the receptor constituted about 70% of the protein recovered after SEC, and was present in
all of the samples.
2.3.5 Structural Characterization of Purified hVN1R1
Circular dichroism (CD) was used to determine whether the FC14-solubilized and
purified hVN1R1 was properly folded (Figure 2.4). Far and near UV were used to probe
the secondary and tertiary structure of the purified receptor. Figure 2.4A shows the far
UV spectrum. The CD spectrum showed a characteristic a-helical shape with valleys at
about 208 and 220 nm. This is expected, since hVN1R1 is a GPCR with 7 predicted
transmembrane helices. Figure 2.4B shows the near UV spectrum. The near UV spectrum
indicates that the purified VN1R1 has a well-defined tertiary structure, as misfolded
receptors are not expected to yield any peaks or show a CD trace [3, 31]. Together, the CD
spectra suggest that HEK293-expressed hVN1R1 is properly folded, and that FC14 is able to
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maintain this structure once the receptor has been extracted from the cell membrane and
purified.
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Figure 2.4. Circular Dichroism Spectra of Purified hVN1R1. A) Far UV trace showing a curve
characteristic of an alpha-helix. This shape is expected, as hVN1R1 is a GPCR with seven predicted
transmembrane helices. B) Near UV trace. The peaks indicate that the protein has a well-defined
tertiary structure.
2.3.6 Ligand Binding Characterization of Purified hVN1R1
Microscale thermophoresis (MST) was used to determine whether the FC14
solubilized receptor could bind its ligand myrtenal (MW 152.23). MST is the directed
movement of molecules along a spatial temperature gradient This movement is sensitive
to changes in the hydration shell surrounding the molecule. Ligand binding alters this shell
in a way that measurably changes the molecules' thermophoretic movement [17, 18, 32].
Unlike SPR or other surface-based techniques, MST does not require immobilization. The
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molecules are monitored in free solution. Additionally, proteins can be tracked by
detecting the fluorescence of native tryptophans. Coupling chemistries or other
modifications that could potentially alter a receptor's function are thus not necessary.
The purified monomeric form of hVN1R1 was used for ligand-binding
measurements. Samples were titrated with varying concentrations of myrtenal. Myrtenal
has been reported as a ligand with an expected ECso of -22[tM in HeLa/Olf cells [14].
Figure 2.5 shows the MST titration curves normalized to the fraction of bound receptor.
The monomer exhibits a plateau at low concentrations and at high concentrations. Fitting
the Hill equation to the data yields a KD of ~1pM. This result is similar to the result
reported by Shirokova et al, and is also in the same range as KD values measured for
olfactory receptors [3, 33]. Boiled controls under otherwise identical conditions did not
exhibit any plateaus, demonstrating that the measured changes in thermophoretic
amplitude resulted from myrtenal binding to hVN1R1. Future studies must be performed
to determine the effect dimerization has on hVN1R1 function: because the monomeric form
is present in all receptor samples even after SEC, it was not possible to obtain sufficient
quantities of pure dimerized hVN1R1 for ligand binding analysis.
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Figure 2.5. Ligand Binding of Purified hVN1R1 Using Microscale Thermophoresis. A) A
sample of hVN1R1 was titrated against varying concentrations of myrtenal, and its thermophoretic
mobility was measured. The plateaus at low and high myrtenal concentrations indicate that the
receptor is binding its ligand with an ECso-1iiM. B) A boiled control did not exhibit the
characteristic sigmoidal binding curve, indicating that the assay was indeed measuring binding
between hVN1R1 and myrtenal. Since no binding was observed, the boiled control was not
normalized to a fraction of bound receptor.
2.4 Discussion
This study shows that HEK293 cells can be used to generate milligram quantities of
a human vomeronasal receptor. A pure and homogeneous protein sample was obtained
through controllable, inducible expression. The purified receptors had alpha helical
secondary structures, indicating that they were properly folded. They were also able to
bind their reported ligand, and the measured ECso value matched what has been previously
reported.
A growing body of evidence suggests that HEK293 cells are a suitable platform for
expressing GPCRs, and that FC14 is a universally effective detergent for solubilizing and
stabilizing them. HEK293 cells have successfully been used in previously reported studies
to produce rhodopsin and the olfactory receptor hOR17-4 [1-3]. All of the tested cultures
yielded large quantities of receptors that could be easily purified using the rholD4 epitope
and antibody. This study further showed that removal of predicted glycosylation sites does
not inhibit membrane localization or ligand binding. Although this study only used cells
grown on tissue culture plates, previous reports have shown that HEK293 cells can be
grown in suspension to yield even larger quantities of receptors [3]. Numerous studies
have shown that the fos-choline series of detergents best solubilize GPCRs. In large
screens, the fos-choline series consistently was equal to or outperformed other detergents
for the GPCRs OR17-4, CCR3, CCR5, CXCR4, CX3CR1, hVN1R1, and hTAAR5 [3, 16, 30].
Although FC15 and FC16 were able to solubilize a greater quantity of expressed receptor
than FC14, all three detergents were able to solubilize comparable amounts. Since FC14
has a CMC that is high enough to allow for detergent exchange, has been used to obtain high
resolution protein structures [28, 29], and can be used for both the solubilization and
purification processes, it appears to be an excellent detergent that may be broadly useful.
However, both the HEK293 platform and the detergent must still be evaluated for every
GPCR to verify their effectiveness.
2.4.1 Existence of Functional Human Vomeronasal Receptors
The results reported here suggest that humans have functional VNR genes, while
previous reports suggest that human VN1Rs may function more like olfactory receptors.
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This is the first report showing direct binding between a vomeronasal receptor and a
volatile ligand. This study and previous reports show that the receptors are likely to have
binding affinities in the [tM range [14], that they can couple to the canonical OR signaling
pathway via G~oif and G.s and cAMP [14], and that hVN1R1 mRNA is expressed in the human
MOE [15]. Indeed, mouse VN1Rs signal through TRP, which is a pseudogene in humans. If
human VN1Rs are biologically functional, they must have a different signaling mechanism
that still needs to be elucidated. The HEK293 cells used in this study provide an excellent
mechanism to perform such studies. These cells have been successfully used to express
and purify other GPCRs including the olfactory receptor OR17-4 [1-3]. They can thus be
used as a platform to compare OR and VNR function and signaling. Additionally, although
the human VNO may not be a functional organ, expression of hVN1R1 mRNA in other
tissues in addition to the MOE raises the possibility that human vomeronasal receptors
may have non-olfactory functions. Indeed, OR17-4 functions in both olfaction and sperm
migration [34].
2.4.2 Technological Importance of Membrane Proteins
Membrane proteins are critical for communication between the cellular and
external environments, and have potential uses in medicine and the design of biologically-
based devices. They comprise nearly 25-30% of genes in sequenced genomes, and are
involved in various processes ranging from chemical transport, signal transduction, and
photosynthesis. GPCRs, the largest subclass of membrane proteins, are the target of nearly
50% of pharmaceutical drugs [35-38]. Olfactory-related proteins (ORs, VNRs, TAARs, and
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FPRs) are the largest subclass of GPCRs, and could potentially be used to develop highly
sensitive detectors.
Detailed structural knowledge of membrane proteins is therefore critical for
developing new technologies and medicines. Yet, in spite of their enormous potential, very
little is known about membrane protein structures. Of the >72,000 protein structures
known, only 281 are unique membrane proteins, and only 6 are unique GPCRs as of April
2011. To facilitate protein structure determination, fast and reliable methods of protein
expression and purification must be developed. In addition to hVN1R1, the methods used
in this study have been successfully used with bovine rhodopsin and OR17-4 [1-3]. This
study further showed that the expressed proteins are functional and targeted to the
membrane even when potential glycosylation sites have been removed. This further
underscores the potential for this system to be used with a wide variety of membrane
proteins in preparation for crystallization trials. These efforts to purify hVN1R1 may not
only help understand the role and function of the human vomeronasal system, but could
also contribute toward other membrane protein studies and the development of
biologically-inspired technologies like artificial noses.
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CHAPTER 3
INVESTIGATION OF T4 LYSOZYME
AS A STRATEGY TOWARD GPCR
CRYSALLIZATION
3.1 Introduction
Once sufficient quantities of membrane proteins have been produced and purified to
allow for crystallization screens, and a suitable detergent has been found, other obstacles
to crystallization must be overcome. Three such difficulties are primarily encountered.
First, the detergent used to solubilize the protein forms a protective belt, severely
decreasing the number of potential protein-protein contacts available to form a crystal.
Second, large regions of the protein may be disordered as a result of its secondary
structure or post-translational modifications. This heterogeneity of structure prevents a
regular lattice from forming. Third, the protein may not remain stable for the amount of
time necessary for crystal formation to occur.
Several novel strategies have been developed to facilitate membrane protein crystal
growth. To increase the surface area available to form a crystal lattice, T4-lysozyme (T4L)
fusions have been synthesized [1-4], and antibody fragments against specific portions of
the membrane protein have been used [5]. These antibody or T4L fragments are soluble
proteins that effectively increase the solvent-exposed receptor area, thereby facilitating
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protein-protein contacts needed for crystal formation. To increase the structural
homogeneity of a protein sample, loops and other large protein segments without a defined
and stable secondary structure have been deleted, and post-translational modifications like
glycosylation have been removed [1-3,5, 6]. To improve protein stability, sequence
mutations have been introduced [2,4,6].
Current strategies are rationally designed, but must be empirically tested with each
membrane protein. The most beneficial strategy in membrane protein structural research
would be one that could be used with many proteins. Insertion of T4L in the third
intracellular loop seems to be a promising technique for GPCRs, as four of the six
crystallized GPCRs used this approach [1-4]. Generation of DNA templates is fast and easy
using current cloning techniques. Unlike the development of antibody fragments, it isn't
necessary to spend months to find a specific variant for the protein of interest. Instead,
many DNA templates can easily be generated in parallel. This method also allows the
entire protein or the majority of it to be crystallized. However, insertion of T4L near the
putative G-protein binding domain can disrupt receptor function. It can also potentially
interfere with proper folding, limiting the useful information that could be obtained from
the crystal structure. It is thus necessary to evaluate how a T4L insert can affect the
function and structure of various GPCRs.
This study examines the ability of T4L to be used as a general insert in olfactory-
related GPCRs. Native and T4L-mutants of hOR17-4 and hVN1R1 were expressed in
HEK293 cells. The structure and function of the T4L variants were compared to the native
forms. Immunocytochemistry showed that both protein forms were localized to the cell
surface, and calcium influx assays indicated that they could initiate signaling. Circular
dichroism and microscale thermophoresis analyses of purified receptors showed that the
native and T4L-mutants had alpha-helical structures and bound their ligands.
Interestingly, the T4L-mutants yielded higher percentages of soluble monomers compared
to aggregates, indicating that the T4L insert stabilized the protein structure. The mutants
also had lower ligand-binding affinities, but yielded more consistent results over time with
less noise, further suggesting higher receptor stability. These results indicate that a T4L
insertion may be a viable option when working with GPCRs with the goal of obtaining a
crystal.
3.2 Methods
3.2.1 hOR17-4T4L and hVN1R1-T4L Gene Design and Construction
The protein sequences for hOR17-4 (NCBI Accession #NP002539) and hVN1R1
(AAG10698) were obtained from GenBank. To enable expression and purification from
mammalian cells, the following modifications were made to both genes: 1) addition of a C-
terminal rho tag (TETSQVAPA) preceded by a two glycine linker; 2) human codon
optimization; 3) addition of a Kozak sequence 5' to the start codon; 4) addition of a 5' EcoRI
site and a 3' Xhol site to facilitate subcloning into expression vectors. 5) addition of an N-
terminal strep tag (ASWSHPQFEK) followed by a GSSG linker for further purification; 6)
insertion of T4 Lysozyme residues 2-161 in the predicted third intracellular loop after
residue S232 in hOR17-4 and after residue L261 in hVN1R1; and 7) N5Q and N195Q
mutations in hOR17-4, and N117Q, N151Q, and N183Q, N198Q, and N256Q mutations in
hVN1R1 to facilitate crystallization. The genes were constructed by Geneart and ligated
into the pcDNA 4/To vector (Invitrogen, Carlsbad, CA). The plasmid was amplified in
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subcloning efficiency DH5a E. coli (Invitrogen) and purified using MiniPrep or MaxiPrep
kits (Quiagen, Valencia, CA). The transmembrane and loop domains were predicted using
the TMHMM Server v 2.0 (http://www.cbs.dtu.dk/services/TMH MM/). The DNA
sequences for hOR17-4 [8] and hVN1R1 (Chapter 2) were synthesized as previously
described.
3.2.2 Expression, Purification, and Structural and Functional Analyses of T4L
Mutants
The generation of stable, inducible cell lines capable of expressing the desired
proteins is described in Chapter 2. Methods for purifying the receptors and analyzing their
structure and function are also described.
3.2.3 Calcium Influx Imaging
HEK293 cells expressing hOR17-4 or hOR17-4T4L were seeded on 0.18 mm thick
cover-glass slides at a densitiy of 10s cells/ml. OR expression was induced with 1 Jtg/ml of
tetracycline for 48 h. To visualize calcium signaling, cells were loaded with 10 1M Fura-
Red-AM (Invitrogen) for 30 min in serum-free DMEM/F12 medium and washed in PBS.
The cells were then incubated an additional 30 min in DMEM/F12 supplemented with 10%
FCS to allow intracellular Fura-Red-AM to completely hydrolyze. Calcium influx in
response to 50 gM of the odorant bourgeonal was visualized using confocal fluorescence
microscopy (Zeiss LSM 510) with a water immersion objective (Zeiss Achroplan 63 x NA
1.2). The cells were excited at 488 nm (Ar+ laser), and fluorescence emission of Fura-Red-
AM was monitored at 650 nm using a long pass emission filter. Images were collected
every 2 seconds for a total of 100 seconds. ATP was used as a control. Unless noted
otherwise, cells were incubated at 37*C and 5% CO2 in DMEM (Dulbecco's modified Eagle's
medium, Invitrogen, San Diego, CA) supplemented with 10% FCS (Invitrogen). Calcium
imaging of hVN1R1 and hVN1R1-T4L cells was not performed due to the higher toxicity of
expressing the proteins, and because it is not known whether the receptors are capable of
coupling to the endogenous HEK293 G-proteins [7]. Any results obtained with these cell
lines would thus be ambiguous. These experiments were performed with the help of Dr.
Horst Pick from the Institut des Sciences et Ingenierie Chimiques, Ecole Polytechnique
Fed6rale de Lausanne (EPFL).
3.3 Results
3.3.1 Induction of hOR17-4T4L and hVN1R1-T4L Expression in Stable HEK293 Cell
Lines
The native forms of hOR17-4 and hVN1R1 were previously expressed [8, 9, Chapter
2]. The T-Rex system was used to make the T4L variants in the same manner as the native
receptors. Final induction conditions for hOR17-4T4L were 1ptg/ml of tetracycline with
5mM sodium butyrate, and for hVN1R1 were 1 Kg/ml of tetracycline with 1mM sodium
butyrate. All inductions were performed for 48 hours prior to harvesting the cells for
receptor purification.
The expressed protein was analyzed using SDS-PAGE and Western blotting. Both
T4L clones had two bands, corresponding to the monomeric and dimeric forms of the
receptor (Figure 3.1). The presence of this characteristic size pattern indicates that the
T4L insert does not significantly alter receptor folding or function, as both GPCRs are
capable of forming dimers.
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Figure 3.1. Expression of hOR17-4T4L and hVN1R1-T4L in HEK293 Cells. A) hOR17-4T4L, and
B) hVN1R1-T4L. Lane 1 shows receptor solubilized from uninduced cells, lane 2 shows receptor
solubilized from cells induced with 1[ig/ml of tetracycline for 48 hours, and lane 3 shows receptor
solubilized from cells induced with 1jg/ml of tetracycline and 5mM sodium butyrate for 48 hours.
No protein was detected in uninduced cells. Induction with tetracycline and sodium butyrate
resulted in maximum expression. Both receptors had monomeric and dimeric forms. Subsequent
experiments determined that the optimal sodium butyrate concentration was 5mM for hOR17-
4T4L, and 1mM for hVN1R1-T4L.
3.3.2 Immunohistochemical Staining of Induced Cells
GPCRs often become trapped in the cell when expressed in heterologous systems.
This is particularly true when post-translational modifications like glycosylation are
removed, suggesting that the conserved N-terminal glycosylation site of ORs may be
necessary for appropriate localization [10-16]. To determine whether the stably expressed
hOR17-4T4L or hVN1R1-T4L receptors were trafficked to the cell membrane, induced and
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non-induced cells were stained with the rho1D4 antibody (Figure 3.2). Non-induced cells
yielded no signal, while induced cells showed receptors that were localized to the cell
membrane. Permeabilized and non-permeabilized cells both demonstrated membrane
localization, suggesting that not all receptors are inserted in the correct orientation.
However, visualization of both native and T4L-mutant proteins in the membrane indicates
that the T4L insert does not affect GPCR trafficking. The results also indicate that the
glycosylation sites are not necessary for localization of the protein to the membrane.
Figure 3.2. Immunohistochemical Staining of Native and T4L Clones. A) Uninduced hVN1R1;
B) Induced hVN1R1; C) Uninduced hVN1R1-T4L; D) Induced hVN1R1-T4L; E) Uninduced hOR17-4;
F) Induced hOR17-4; G) Uninduced hOR17-4T4L; H) Induced hOR17-4-T4L. The noninduced cells
express undetectable amounts of receptor. The expressed receptors are localized to the cell
membranes. Panel E was overexposed to visualize the cells; some leaky expression can be seen in a
few cell membranes, but otherwise no surface-localization can be seen.
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3.3.3 Functional Characterization of hOR17-4T4L in HEK293 Cells
The functional activity of hOR17-4T4L was probed by measuring the influx of
calcium ions in response to the specific odorant bourgeonal [17, 18]. In HEK293 cells,
hOR17-4 can couple to the promiscuous G protein Gcq to initiate a signal through the
inositol triphosphate (IP3) pathway [8,9]. Similar results were observed with hOR17-
4T4L: application of 50pM bourgeonal resulted in a transient increase in intracellular Ca+2
concentration (Figure 3.3). However, this Ca+2 response was 60-70% lower than the
native protein. Also, the time needed to return to baseline Ca+2 levels after induction was
shorter (5-10 seconds for hOR17-4T4L, and 25 seconds for hOR17-4). These results show
that hOR17-4T4L is capable of signal transduction, although perhaps in a reduced capacity.
The receptors hVN1R1 and hVN1R1-T4L were not tested due to the higher levels of cell
toxicity.
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Figure 3.3. Ca+2 Influx Profiles for A) hOR17-4T4L and B) hOR17-4 Expressed in Stable,
Inducible HEK293 Cells. Responses from three individual cells (nos. 1, 2, 3) are shown for hOR17-
4T4L, and two individual cells (nos. 1, 2) for hOR17-4. The intracellular Ca+2 concentration was
monitored with confocal microscopy using Fura-Red as an indicator. The intensities are displayed
in pseudo color (A and B, top). The cytosolic Ca+2 concentration is recorded as a function of time (A
and B, bottom). The arrows indicate the time at which the odorant bourgeonal was applied. 100 M
ATP was used as a control. The profiles show that both proteins initiate signal transduction, though
the response from hOR17-4T41 is lower in amplitude and shorter in duration. The size bar is 10im.
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3.3.4 Systematic Detergent Screening for Receptor Solubilization
An appropriate detergent must be used to solubilize receptors from cell membranes,
and keep them stable and functional in solution. A confounding factor is that different
detergents may need to be used even for similar or related proteins, and must therefore be
empirically determined. Thus, although optimal detergents for hOR17-4 and hVN1R1 have
been experimentally determined [9, Chapter 2], new detergent screens were performed for
hOR17-4T4L and hVN1R1-T4L.
The optimal detergents for hVN1R1-T4L and hOR17-4T4L were again the fos-
choline series (Table 3.2). The receptors hVN1R1, hVN1R1-T4L, and hOR17-4 had nearly
identical detergent profiles, which were also similar to the profiles reported for several
other GPCRs [9, 19]. In contrast, hOR17-4T4L exhibited a slightly different profile. For
hVN1R1, hVN1R1-T4L, and hOR17-4, receptor solubility was vastly improved in the fos-
choline detergents compared to most of the other detergents. Only a handful of other
detergents were able to solubilize comparable amounts of protein. While receptor
solubility for hOR17-4T4L was higher in the fos-cholines than in any other detergent class,
many other detergents were able to solubilize sufficient quantities of receptor. The cyclo-
fos and anzergent families yielded only slightly less soluble protein than the fos-cholines, as
well as Fos-MEA-10 and FOSFEN-9. This similarity is not surprising, as these detergents
have similar structures (Table 3.1). The only difference between the fos-cholines and
cyclofos detergents is a cyclohexane ring at the end of the cyclofos carbon chain. Similarly,
FOSFEN detergents have a phenyl ring attached to the carbon chain. Fos-MEA detergents
are similar to the fos-cholines, except that 2 methyl groups on the choline nitrogen have
been replaced with hydrogens. The anzergents exhibit slightly greater differences: they
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have a sulfate group instead of a phosphate group, and the order of the negatively and
positively charged groups is reversed. All of these detergents are structurally or chemically
similar to phosphatidylcholines, phospholipids that are major constituents of cell
membranes. Thus, although hOR17-4T4L has a different detergent profile than the other
tested GPCRs, these results reinforce increasing evidence that detergents that are
structurally related to biological phospholipids are optimal detergents for GPCRs. It should
be noted that several other detergents, including the maltosides, were able to solubilize
noticeable amounts of protein. However, they were not as effective as the fos-cholines or
related detergents.
Table 3.1: Detergent Structures
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3.3.5 Purification of hOR17-4T4L and hVN1R1-T4L
A two-step purification procedure using immunoaffinity chromatography and size-
exclusion chromotagraphy (SEC) was used to purify the expressed receptors [8,9, Chapter
2].
While UV absorption at 280 nm typically showed three distinct peaks for the native
proteins, it usually showed only two for the T4L mutants. Western blot analysis
demonstrated that the three native peaks corresponded to aggregated, dimerized, and
monomeric forms of the protein [8, 9, Chapter 2]. Similar analyses of the T4L-mutants
showed that the peaks corresponded to dimerized and monemeric protein forms (Figure
3.4). There was little or no evidence of aggregated receptor. The UV readings also
indicated that a higher percentage of the total protein obtained was soluble monomer.
These results suggest that the T4L insert may help stabilize the receptor in a soluble state,
and that a higher proportion of protein purified from a T4L-mutant batch will be usable for
crystallization screens. Both native and T4L-mutant proteins were able to yield about 1mg
of total protein per gram of cells. However, depending on the purification batch, at least
50% and up to 60-70% of the protein recovered after SEC was soluble monomer for the
T4L clones. In contrast, ~10-40% of the protein recovered after SEC was soluble monomer
for the native clones.
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Figure 3.4. 280 nm UV Traces Through a Size Exclusion Column and a Silver Stain of the T4L
Fractions. A) Typical 280 nm UV trace of hVN1R1, B) Typical 280 nm UV trace of hOR17-4, C)
Typical 280 nm UV trace of hVN1R1-T4L, D) Typical 280 nm UV trace of hOR17-4T4L, and E) Silver
stain of the purified samples in C) and D). Peak 1 from D) is not shown, but contained primarily
aggregated protein. The native proteins yield more aggregrated receptors. The T4L mutants are
primarily a monomeric population. This suggests that the T4L insert prevents aggregation by
keeping the receptors soluble in the monomeric or, secondarily, dimerized state. Number code: 1)
Aggregate; 2) Dimer; 3) Monomer. Blots of peak fractions in A) and B) have been reported in [9]
and Chapter 2.
3.3.6 Structural Characterization of Purified hOR17-4T4L and hVN1R1-T4L
The secondary structure of the T4L mutants was assayed using circular dichroism
(CD). Far UV spectra of both proteins have characteristic alpha-helical shapes, similar to
the native proteins (Figure 3.5). However, the peaks at 208 and 220 nm are more defined
in the T4L mutants. A CD spectrum is assumed to be a linear composition of the individual
spectra of each secondary structure present in the tested protein. A protein that is purely
alpha-helical in shape will have sharply defined peaks at 208 and 220 nm, while a protein
that has a higher percentage of loops and random coils will have peaks that are less
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pronounced [21]. These results thus suggest that the T4L insert may help to structurally
stabilize the proteins.
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Figure 3.5. Circular Dichroism Spectra of Native and T4L GPCRs. A) hOR17-4 and hOR17-
4T4L. B) hVN1R1 and hVN1R1-T4L. The native and T4L variants have alpha-helical secondary
structures. However, the peaks are more pronounced in the T4L mutants, suggesting that the
structure is more stabilized.
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3.3.7 Ligand Binding Analysis of Purified hOR17-4T4L and hVN1R1-T4L
Microscale thermophoresis (MST) was used to determine whether the native
proteins and T4L mutants could bind their ligands. Microscale thermophoresis is a
technique that induces a local spatial temperature gradient. Proteins in the gradient
diffuse along it. Free receptors have a different diffusion pattern compared to receptors
that are bound to their ligands, likely due to changes in their hydration shell [22, 23]. MST
can measure binding of ligands as small as individual ions [24], which is critical because
odorants are less than 300Da while their receptors are larger than 30kDa. MST can also be
used on receptors in solution, and can detect fluorescence from native tryptophans,
thereby eliminating the need to use surface or coupling chemistries, which can alter the
structure or function of the protein being studied.
The native and mutant proteins were titrated against their known ligands. For both
proteins, the T4L mutant had a lower ligand-binding affinity than the native protein, but
was still able to bind the ligand (Figure 3.6). Interestingly, the binding analyses indicated
that the T4L insert stabilized the receptor, even though it also probably disrupted the
ability of the receptor to bind its ligand. Measurements taken on the same sample of
hOR17-4T4L over two months apart yielded the same results, while similar measurements
of hOR17-4 were noisier and less consistent.
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Figure 3.6. Ligand Binding Measurements of Native and T4L GPCRs. A) hVN1R1
binding to myrtenal with an ECso ~1ptM. B)hVN1R1-T4L binding to myrtenal with an
ECso~9iiM. C) hOR17-4 binding to canthoxal with an ECso ~30iM. D) hOR17-4T4L binding
to canthoxal with an ECso -70pM. The native and T4L mutants were able to bind their
ligands, but the T4L variants had lower affinities. Boiled controls did not bind their ligands,
and had behavior similar to that observed in Chapters 2, 4, and 5. For clarity, they are not
shown. All curves are normalized to the fraction of bound receptor, and are fit to the Hill
equation with a coefficient of 2.
3.4 Discussion
In spite of their importance, knowledge about the structure and function of
membrane proteins in general, and specifically GPCRs, lags far behind that of soluble
proteins. This is mainly due to the difficulty of expressing and solubilizing functional
receptors, as well as the difficulty of crystallizing any proteins that are produced.
Structural knowledge of a protein is necessary in order to fully understand its function. It
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is especially important with respect to GPCRs, as a determination of their structure could
enable the design of specific drugs or biologically-inspired technologies.
A significant challenge in the field of membrane protein crystallography lies in
finding strategies that can be applied to multiple proteins. Indeed, crystallization
conditions for even similar or related proteins are unique and must be empirically
determined [25]. Insertion of T4 Lysozyme in the third intracellular loop of GPCRs seems
to be a promising approach, as 4 of the 6 structures to date were obtained using this
strategy. However, to be truly useful, this approach should not only facilitate
crystallization, it should also not interfere with the normal structure and function of the
protein. This study has examined how addition of the T4L sequence in the third
intracellular loop affects expression, solubilization, purification, folding, and function of
two olfactory-related GPCRs.
The detergent screens indicated that insertion of T4L can alter the optimal
detergent for the protein. The receptors hVN1R1 and hVN1R1-T4L had similar patterns of
solubility in the tested detergents, while the solubility pattern of hOR17-4 and hOR17-4T4L
was more variable. However, in both cases, the optimal detergents for both native and
mutant proteins belonged to the same general class, and had similar structures or chemical
properties.
Results obtained during the purification process indicate that insertion of T4L may
help increase the yield of soluble protein for crystallization screens. Size-exclusion
chromatography showed that -10-40% of the recovered native protein was soluble
monomer. In contrast, at least 50%, and up to 70%, of the recovered mutant protein was
soluble monomer. This is an important finding, because milligram quantities of
homogeneous protein are needed for crystallization trials and other structural studies.
Aggregation or impurities are common, and severely limit the amount of usable protein
typically obtained after a batch purification. Indeed, up to 90% of the receptor obtained
from the native proteins was aggregated or impure, and could not be used for subsequent
experiments. Addition of T4L increased the yield of usable receptor, likely due to its
solubility, which increased the solubility of the fusion protein. In addition, the CD and MST
measurements indicated that the T4L insert may help stabilize the protein in which it is
inserted; both T4L mutants had more defined CD spectra, and hOR17-4T4L was able to
bind its ligand several months after it was purified. This is particularly important, as
several months may be needed for crystal growth.
Immunohistochemical data, calcium influx assays, circular dichroism, and
microscale thermophoresis indicate that insertion of T4L in the third intracellular loop
does not completely disrupt protein structure or function. Both T4L mutants trafficked to
the cell membrane. Because membrane localization can be impaired for improperly folded
or glycosylated GPCRs, this suggests that the T4L insertion does not adversely affect
receptor structure. Circular dichroism showed that the purified proteins had alpha-helical
conformations, indicating that they were properly folded. Indeed, the T4L mutants had
more defined peaks, suggesting that they might be more stable. Calcium influx assays in
HEK293 cells demonstrated that signaling still occurred with the hOR17-4T4L mutant,
although it was more limited. Microscale thermophoresis measurements of purified
receptors showed that the T4L mutants had higher ECso values, but were still able to bind
their ligands. The latter two results indicate that the insert may interfere with G-protein
interactions, as well as with ligand binding. Since GPCRs are known to have many flexible
conformations, it's possible that the T4L insertion may stabilize a particular conformation,
making binding of certain ligands more difficult. Thus, although lower binding affinities
were measured with canthoxal (hOR17-4) and myrtenal (hVN1R1), it is possible that
interactions with other ligands would be less affected, or might even have higher affinities.
Future experiments will be carried out to test this hypothesis.
Structural knowledge of GPCRs and other membrane proteins is a prerequisite for
the design of specific therapies or biologically-inspired technologies. Insertion of T4
Lysozyme in the third intracellular loop seems to be a promising strategy for GPCR
crystallization, as four of the six crystallized GPCRs have a T4L insertion. The results
presented here further support this. Comparison of native and T4L mutants of hOR17-4
and hVN1R1 indicates that T4L helps to solubilize and stabilize the proteins, as well as
increase the yield of protein that is usable for crystallization screens. Membrane
trafficking, calcium influx assays, and ligand binding analysis show that the T4L mutants
maintain some biological activity. These results indicate that this may be a promising
strategy for a wider range of GPCRs, and potentially other membrane proteins. This
strategy may thus help facilitate crystallization of a broader range of GPCRs.
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CHAPTER 4
A ROBUST AND RAPID METHOD OF
PRODUCING SOLUBLE, STABLE, AND
FUNCTIONAL G PROTEIN-COUPLED
RECEPTORS
This chapter is an expansion of a manuscript accepted by PLoS ONE:
Corin, K., Baaske, P., Ravel, D.B., Song, J., Brown, E., Wang, X, Wienken, C.J., Geissler, S.,
Jerabek-Willemsen, M., Duhr, S., Braun, D. & Zhang, S. (2011) A robust and rapid
system for studying functional G-protein coupled receptors. PLoS ONE, (In press).
4.1 Introduction
G-Protein Coupled Receptors (GPCRs) are the focus of intense research, as they are
the largest class of integral membrane proteins and are the targets of -50% of
pharmaceutical drugs. A critical bottleneck in GPCR studies has been the difficulty of
expressing soluble and stable receptors in sufficient quantities to allow for rapid progress
in structure and function studies. In order for this to occur, a rapid, simple, cost-effective
and high-yield method of producing GPCRs must be found.
Cell-free in vitro translation is an alluring technology for the expression of GPCRs
because experiments with soluble proteins show that it has the potential to fulfill the
above-stated requirements. Unlike expression in eukaryotic or bacterial cells, protein can
be produced within several hours directly from plasmid DNA. The typical issues of cell
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toxicity, protein degradation, protein inhomogeneity, and aggregation in internal
compartments or inclusion bodies do not arise.
Although cell-free in vitro translation is a mature technology for expression of
soluble proteins, it has only recently been used to express membrane proteins [1-16]. This
is due primarily to the necessity of including a detergent capable of solubilizing and
stabilizing the newly synthesized proteins without interfering with transcription or
translation. Finding an optimal detergent is expensive and laborious. Several studies
indicate that mild detergents like polyoxyethylene derivatives may be effective [3, 14], but
only a limited number of proteins have been successfully tested [1-15], and most published
reports have limited their studies to one or few proteins.
Although these reports are promising, four areas must still be addressed for cell-
free expression to become a practical and widely useful technology for producing GPCRs.
First, milligram quantities of receptor must be able to be consistently produced and
purified. Second, cell-free expression methods must be sufficiently robust to work with a
wide variety of proteins. Often, specific expression platforms work well only with a limited
number of membrane proteins, and even then they must often be optimized for a given
protein. It is thus necessary to demonstrate that cell-free GPCR expression is feasible for
numerous GPCRs. Third, cell-free expressed proteins must be directly compared to those
produced in mammalian cells or purified from native tissues. Many GPCRs require post-
translational modifications for structural stability or biological function. E. coli and wheat
germ extracts do not contain the necessary machinery. Thus, it must be demonstrated that
the structure and ligand-binding affinities of cell-free expressed receptors are similar to
those of native receptors. No published study has directly compared a cell-free GPCR to a
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counterpart expressed in mammalian cells to verify that the cell-free constructs are indeed
viable. Fourth, many studies have only used cell-free systems developed in individual
laboratories [1-13], which are thus not available for widespread use. In order for cell-free
technology to truly benefit the entire GPCR and membrane protein research community,
commercial reagents are optimal to minimize variations in sample preparations from each
laboratory. It would therefore be advantageous if commercial cell-free systems currently
used for soluble proteins could be optimized for large-scale GPCR expression.
In this study, commercial cell-free translation systems were used with Brij-35 for
the rapid, high-yield production of 13 GPCRs (Table 4.1), including 9 olfactory receptors
(ORs), one human trace-amine receptor (hTAAR5), one human formyl peptide receptor
(hFPR3), and 2 human vomeronasal receptors (hVN1R1 and hVN1R5). The expressed
GPCRs could be purified to >90%, were properly folded, and were able to bind their
ligands. The GPCR hVN1R1 was stably cloned into HEK293 cells. The HEK293 and cell-free
expressed hVN1R1 had comparable structures and ligand-binding properties.
4.2 Methods
4.2.1 GPCR Choice
Nine diverse olfactory receptors were chosen for this study (Table 4.1). The
receptors were of human, mouse or rat origin, and came from both Class I and Class II type
receptors. Because of the necessity of measuring OR-ligand interactions to show
funtionality, only ORs with known ligands were chosen. The chosen ORs have been
reported to respond to chemically diverse odorants.
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Only human receptors were chosen from the remaining olfactory-related GPCR
families. Most studies examine mouse receptors due to the relative ease of studying how
these receptors function in their native environment. Cell-free expression can make the
human receptors more amenable to study, which may help elucidate differences between
the human and mouse sense of smell. Two human vomeronasal receptors with known
ligands were chosen (Table 4.1). Although the existence of a functional human
vomeronasal organ is debated, the chosen receptors have been expressed in HeLa Olf cells,
and have been shown to initiate the canonical G-protein signalling pathway upon exposure
to their ligands [17]. They also have intact reading frames in the human genome. The
receptor hVN1R1 was chosen because studies have reported mRNA expression in several
tissues, including the olfactory epithelium [18]. It also has a high sequence homology to
mouse and rat VNRs, and contains the same conserved residues [18]. The receptor
hVN1R5 was chosen because it is least homologous to the other 4 human VNRs, as well as
VNRs in other species [19], and therefore represents an intriguing point of comparison.
The human hTAAR5 gene was chosen because it is phylogenetically unique [20]. Also, it
does not bind to the same ligands as its mouse orthologue, suggesting different functions in
mice and humans [21]. Although an olfactory role for the human FPRs has not been
demonstrated, the receptor hFPR3 was chosen. Because these receptors function in the
immune system, expression of an active receptor would indicate that cell-free technology
can be expanded to broader classes of GPCRs, and is not limited solely to those involved in
olfaction.
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Table 4.1: Expe imental GPCRs and Thei Properities
Receptor Name Amino Molecular Ligands Species
(Accession Acids Weight (Da)
Number)
mOR33-1 331 36686.00 Aliphatic alcohols Mouse, Class I
(GenBank and carboxylic
AAL60676.1) acids [22]
mOR103-15 340 37324.02 Heptanal Mouse, Class 11
(NP_035113.1) [23-25]
mOR106-13 337 37263.62 Aliphatic alcohols Mouse, Class 11
(NP 001011738.1) [22]
mOR175-1 332 37097.23 2-Heptanone, Mouse, Class 11
(SwissProt isoamyl acetate
Q9QYOO.1) 8]
mOR174-4 332 36875.88 Ethyl vanillin Mouse, Class 11
(GenBank [29,30]
BAB59038.1)
mOR174-9 327 36245.05 Ethyl Vanillin, Mouse, Class 11
(NP_473431.1 Eugenol [29-31]_
hOR17-209 326 36097.60 Isoamyl acetate Human, Class 11
(NP_003546.1)
hOR17-210 357 39748.54 Acetophenone Human, Class I1
(SwissProt [32]
Q8WZA6.2)
Olfr226 339 37398.36 2,4-DNT [33] Rat, Class 11
(SwissProt
P23270.2)
VN1R1 40021.02 353 Myrtenal, Human
(AF255342) Carveol, P-lonone
[17]__ _ _ _ _ _ _
VN1R5 40778.58 357 Myrtenal, Human
(AY114735) Carveol, P-lonone
__________________ 
[17]_ _ _ _ _ _ _ _
hTAAR5 337 38242.45 None identified Human
(NP_003958.2)
hFPR3 353 39965.40 F2L, WKYMVM Human
(NP 002021.3) ______ _______ [4 3]___ _____
4.2.2 GPCR DNA Design and Synthesis
The protein sequences of the chosen receptors were obtained from the NCBI online
database (Table 4.1). To facilitate purification and detection of synthesized receptors, the
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rholD4 epitope tag (TETSQVAPA) preceded by a GSSG linker, or a GG linker for the VNRs,
was added to the C-terminus of each protein. EcoRI and Ncol restriction sites were added
to the 3' end, and an Xhol restriction site was added to the 5' end. A second stop codon was
inserted after the original codon to ensure completion of transcription. A Kozak sequence
was added upstream of the start codon to facilitate expression in mammalian cells, if
necessary. The codons for each receptor were optimized for E. coli expression. The genes
were commercially synthesized by GeneArt and subcloned into the pIVex2.3d vector
(Roche Diagnostics Corp.) using the Ncol and Xhol restriction sites. The hVN1R1 gene was
also subcloned into the pcDNA4/To vector (Invitrogen) using the EcoRI and Xhol
restriction sites. This vector was used for mammalian expression, and is described in
Chapter 2. The plasmids were transformed into DH5a cells, amplified, and then purified
using the Qiagen miniprep or maxiprep kits. The final plasmid constructs were verified by
DNA sequencing (MIT Biopolymers Labs, Cambridge, MA).
4.2.3 Cell-Free GPCR Production Using Commercial Kits
E. coli-based cell-free expression kits were used to synthesize the GPCRs according
to the manufacturer's instructions (Invitrogen K9900-97, Qiagen 32506), with the
exception that reactions were performed at 30-33*C. To compensate for the lack of a
natural membrane, detergents were added directly to the reactions. A preliminary screen
determined that the optimal concentration was 0.2% w/v. A final reaction volume of 50[d
was used for all screens. After the reactions were complete, the samples were centrifuged
at 10,000 rpm for 5 minutes. The supernatant containing the solubilized protein was
removed, and the pellet was resuspended in an equivalent volume of PBS. The relative
102
quantities of solubilized and precipitated protein were determined with a western or dot
blot. ImageJ (http://rsb.info.nih.gov/ij/) was used to perform all densitometry analyses.
Final reaction volumes of 0.5-1.0ml were used to produce protein that was purified for
secondary structure and binding analyses.
4.2.4 HEK293 GPCR Production
A stable, inducible HEK293 cell line expressing hVN1R1 was generated as
previously described [36, 37]. Briefly, plasmid DNA was transfected into HEK293G cells
already expressing the pcDNA6/TR vector using Lipofectamine 2000 (Invitrogen). The
transfected cells were grown in selective media containing Zeocin and Blasticidin until
individual resistant colonies were visible. Resistant colonies were picked and screened for
optimal protein expression. The clone with the highest expression level and least toxicity
was selected and amplified for subsequent experiments. Detailed procedures are
described in Chapter 2.
4.2.5 GPCR Detection and Purity Analysis
Western blots and silver stains were used to detect proteins and analyze their
purity. Samples were prepared and loaded in Novex 10% Bis-Tris SDS-PAGE gels
(Invitrogen) according to the manufacturer's protocol, with the exception that the samples
were incubated at room temperature prior to loading as boiling causes membrane protein
aggregation. For blotting, the gel-resolved samples were transferred to a nitrocellulose
membrane, blocked in milk (5% w/v non-fat dried milk in TBST) for 1 hour, and incubated
with a rholD4 primary antibody (1:3000 in TBST, 1 hour at room temperature, or
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overnight at 4*C). The GPCRs were then detected with a goat anti-mouse HRP-conjugated
secondary antibody (Pierce, Rockford, IL) (1:5000 in TBST, 1 hour, room temperature) and
visualized using the ECL-Plus Kit (GE Healthcare). The SilverXpress kit (Invitrogen,
LC6100) was used according to the manufacturer's instructions to perform total protein
stains of the samples. All images were captured using a Fluor Chem gel documentation
system (Alpha Innotech, San Leandro, CA).
4.2.6 Immunoaffinity Purification
CNBr-activated Sepharose 4B beads (GE Healthcare) chemically linked to the
rholD4 monoclonal antibody (Cell Essentials, Boston, MA) were used for immunoaffinity
purification. Solubilized protein from the cell-free reactions was mixed with the bead
slurry (binding capacity 0.7mg/ml) and rotated overnight at 4'C to capture the synthesized
protein. The beads were then washed with wash buffer (PBS + 0.2% FC-14 w/v) until
spectrophotometer readings indicated that all excess protein had been removed (<0.01
mg/ml). The captured GPCRs were eluted with elution buffer (PBS + 0.2% FC-14 + 80011M
elution peptide). The elution peptide Ac-TETSQVAPA-CONH2 was synthesized by CPC
Scientific Inc., CA. Elutions were performed until spectrophotometer readings indicated
that no more protein was present (<0.01mg/ml). The protein was concentrated using
30kDa or 50kDa MWCO filter columns (Millipore, Billerica MA). All concentrations were
measured using the NanoDrop 1000 spectrophotometer (Thermo Scientific). For some
samples, the concentration was also measured with a total protein stain by comparing the
intensity of the GPCR band to the intensity of a BSA band of known concentration. The
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beads were pelleted by centrifugation at 1,400xg for one minute between each wash and
elution.
4.2.7 Secondary Structural Analysis Using Circular Dichroism
Spectra were recorded on a CD spectrometer (Aviv Biomedical, model 410) at 15"C
over the wavelength range of 195-250 nm with a step size of 1nm and an averaging time of
4 seconds. Spectra for purified GPCRs were blanked to wash buffer. A 111-QS quartz
sample cell with a path length of 1mm (Hellma, USA) was used. 300 il of protein sample
was used for each experiment. The spectra were smoothed using an averaging filter with a
span of 5.
4.2.8 Ligand Binding Measurements Using Microscale Thermophoresis
Thermophoresis was used to measure the binding interactions between purified
receptors and their ligands using a setup similar to that previously described [38]. To
eliminate artifacts caused by labeling or modifying proteins, the fluorescence of native
GPCR tryptophans was used to monitor the local receptor concentration. For each tested
GPCR, a titration series with constant receptor concentration and varying ligand
concentrations was prepared in a final solution of 10% DMSO and 0.2% FC-14 in PBS.
Potential autofluorescence of each ligand was checked: no fluorescence signal was
detected from the ligands in the tryptophan fluorescence channel. The final receptor
concentration was 1-2[tM. Approximately 1.5 pl of each sample was loaded in a fused silica
capillary (Polymicro Technologies, Phoenix, USA) with an inner diameter of 300pm. An
infrared laser diode was used to create a 0.12K/pm temperature gradient inside the
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capillaries (Furukawa FOL1405-RTV-617-1480, wavelength X=1480nm, 320mW maximum
power, AMS Technologies AG, Munich Germany). Tryptophan fluorescence was excited
with a UV-LED (285nm), and was measured with a 40x SUPRASIL synthetic quartz
substrate microscope objective, numerical aperture 0.8 (Partec, Goerlitz, Germany). The
local receptor concentration in response to the temperature gradient was detected with a
photon counter PMT P1OPC (Electron Tubes Inc, Rockaway, NJ, USA). All measurements
were performed at room temperature. Fluorescence filters for tryptophan (F36-300) were
purchased from AHF-Analysentechnik (Tilbingen, Germany).
4.3 Results
4.3.1 Cell-Free Detergent Screening
Numerous detergents were systematically screened to assess their ability to produce and
solubilize GPCRs expressed in cell-free systems. The chosen detergents included, among others,
OG, DM, DDM, CHAPSO, Brij-35, Brij-58, and fos-choline14 (FC14). These latter detergents
have effectively solubilized and stabilized GPCRs produced in mammalian cells [36, 37], and
have been used to obtain high-resolution protein structures. Few suitable detergents were found.
The gentle non-ionic detergents tended to work best, with polyoxyethylene derivatives proving
to be the most efficient. Indeed, Brij-35 and Brij-58 yielded ~ 4-5 times more protein than the
next best detergent, with Brij-35 consistently achieving slightly higher yields. Figure 4.1 shows
the results from selected detergents tested with hOR17-210. These results are representative of
results obtained with other receptors, and demonstrate that the choice of detergent is critical.
Detergents commonly used in cell-based production may not be optimal for use in cell-free
systems. Indeed, while FC14 achieved high receptor yields from HEK293 cells, negligible
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protein was detected after cell-free synthesis. This suggests that some detergents may inhibit
transcription or translation by interfering with ribosomes or other synthesis machinery, or by
interacting with nucleic acids.
0.8
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0.4
0.2
Figure 4.1. Detergent Screen for Cell-Free hOR17-210 Production. Brij-35 and Brij-58 yielded
-4-5 times more receptor than the next best detergent. Although comparable, Brij-35 consistently
had slightly higher yields than Brij-58. Each bar represents the average of 2-3 experiments. The
data was normalized to Brij-35, and is representative of results observed with other receptors.
4.3.2 GPCR Expression and Solubility
Because Brij-35 resulted in the highest cell-free expression levels for a subset of the
chosen GPCRs, its ability to solubilize all of the GPCRs was assessed. Western and dot blot
analyses were used to compare soluble and insoluble protein fractions. Without Brij-35,
only -10% of the produced protein is soluble. With Brij-35, up to -93% is soluble (Table
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4.2). This data demonstrates the necessity of using a detergent to prevent aggregation and
potential misfolding of the synthesized proteins. The high solubility level is sufficient to
collect the majority of the expressed protein for downstream applications. Reconstitution
strategies are thus not necessary.
4.3.3 GPCR Purification and Yields
All of the GPCRs were produced in a cell-free reaction, and purified using rho-1D4
antibody tagged beads. The HEK293-expressed hVN1R1 was also purified in a similar
manner. Each receptor was purified in the presence of fos-choline 14 (FC14) because it has
been shown to be the optimal detergent for GPCR purification [36,37,39,40]. Moreover,
this demonstrates the ability to perform a detergent exchange. Since the optimal detergent
depends on both the specific protein and the application, the ability to exchange detergents
is critical.
Figure 4.2 shows a silver stain of 5 purified GPCRs expressed in a cell-free
environment, as well as the HEK293 counterpart. Two bands are visible for each receptor,
corresponding to monomeric and dimeric forms. Dimerization of olfactory receptors has
been reported previously [36, 37, 41, 42], and thus indicates that the cell-free reactions are
producing viable proteins. Dimerization of hVN1R1 has not previously been reported due
to the difficulty of expressing and purifying the protein. However, the occurrence of
dimerization in both the cell-free and HEK293 samples suggests that this expression
pattern is typical for this receptor. Although not shown, all of the ORs, hTAAR5, and hFPR3
displayed a monomeric and dimeric band when run on a gel.
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The purified receptors could be produced at sufficient purity for crystal screens.
Figure 4.2 shows that the receptors were up to 90% pure using immunoaffinity
chromatography alone. Due to the large number of tested GPCRs, 100-1000L cell-free
reactions were performed. The resulting yields were too small to run on a size exclusion
column due to typical protein losses. However, previous studies have demonstrated that
immunoaffinity chromatography followed by size exclusion chromatography (SEC) can
yields receptors over 95% pure. Moreover, SEC can separate the monomer from the dimer,
yielding a pure and homogeneous sample [36, 37]. Indeed, this level of homogeneity and
purity was obtained for the HEK293 VNR1 sample. This level of purity and homogeneity
that can be achieved from cell-free reactions is sufficient for crystallization.
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Figure 4.2. Silver Stains of Purified GPCRs. A) Four cell-free expressed GPCRs. B) Comparison
between cell-free and HEK293 expressed hVN1R1. Most GPCRs could be purified to >90% purity,
and all showed two bands characteristic of a monomer and a dimer [36, 37]. The cell-free and
HEK293 expressed receptors run at the same size, and have similar purities.
The maximum yield of each GPCR after purification was estimated using
spectroscopic measurements at 280nm. Table 4.2 shows the maximum yield of each GPCR
produced in Brij-35. These yields are comparable to those obtained from protein
expressed in mammalian cells, and are sufficient for biochemical and structural studies.
Unlike cell-based protein production, which requires several months, cell-free systems can
produce milligrams of protein within hours directly from plasmid DNA. Cell-free
production of GPCRs is thus a promising and attractive technique for membrane protein
studies.
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Table 4.2: The Solubility and Maximum Yields of 13 GPCRs
GPCR % Yield GPCR % Yield
Solubility (Mg/10ml)* Solubility (Mg/10ml)*
Olfr226 86:t8 3.7 hOR17-209 88:t4 2.5
mOR33-1 85.t2 5.9 hOR17-210 91.t2 4.5
mOR103-15 90 ±4 4.5 hFPR3 83 ±5 5.5
mOR106-13 86±13 2.4* hTAAR5 90±1 4.5
mOR174-4 89 ±2 2 hVN1R1 88± 0.1 0.4
mOR174-9 86 ±3 6 hVN1R5 85± 2 1*
mOR175-1 81±8 2.5
*Milligrams of receptor that could be produced in a 10ml cell-free reaction. These yields were
calculated from smaller batches of protein purified using immunoaffinity chromatography.
Experiments showed that up to 1mg/ml of protein could be produced, but that up to half could be
lost during the purification process. The yields were determined by spectrophotometer readings.
* These proteins were not purified. Yields were calculated by comparing the intensities of the
receptor samples against a sample with a known concentration.
4.3.4 Secondary Structural Analysis Using Circular Dichroism
Circular dichroism (CD) was used to assess the secondary structure of the produced
GPCRs. Figure 4.3 shows the CD spectra of 4 GPCRs. All of the receptors have characteristic
a-helical spectra, with signature valleys at 208nm and 220nm. Since GPCRs have 7-
transmembrane a-helical segments, the spectra suggest that the receptors are properly folded.
The near overlap of the spectra for the cell-free and HEK293 hVN1R1 samples indicates that the
cell-free reactions produce properly folded receptors.
As a control, the receptor mOR103-15 was produced without detergent, and purified
using PBS alone. The CD spectrum of this receptor is characteristic of a random coil [43]
(Figure 4.3), suggesting that it is misfolded. The contrast between this control receptor and
those produced and purified with detergent further suggests that the Brij-produced GPCRs are
properly folded.
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expressed receptors indicates that protein produced in cell-free reactions is comparable to that
produced in cells. mOR103-15 made without detergents has a curve characteristic of a random coil.
Thus further suggests that the receptors expressed in Brij-35 are properly folded, and
demonstrates the necessity of including a detergent.
4.3.5 Ligand Binding Analysis Using Microscale Thermophoresis
Microscale thermophoresis was used to detect binding between the purified GPCRs and
their ligands. Microscale thermophoresis is based on the ligand-binding-induced change in
movement of molecules along a temperature gradient [38, 44]. Unlike surface plasmon
resonance (SPR) or other surface-based techniques, thermophoresis is a label-free and surface-
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free technology that can be used with sample volumes smaller than 5pL per measurement.
Thermophoretic molecular gradients are measured in free solution using the fluorescence of a
protein's native tryptophans. Immobilization and other coupling chemistries that could alter
protein function are thus avoided. Moreover, thermophoresis can detect ligands as small as 40Da
[45]. Most volatile odorants are less than 300Da, whereas their receptors are over 30,000Da
(Table 4.1). Because of the large mass ratio, these binding interactions are extremely difficult to
measure using mass-based technologies, but are possible using microcale thermophoresis [38,
44, 45].
The purified receptors shown in Figure 4.2 were analyzed for ligand binding. Heat-
denatured receptors were used as negative controls, as well as mOR103-15 that was not
expressed in the presence of a detergent. Each native receptor exhibited a typical sigmoidal
binding curve, while the heat-denatured and detergent-free controls had random amplitudes
throughout the ligand titration range (Figure 4.4). These results suggest that the cell-free
produced GPCRs bound their ligands. All of the measured binding affinities were in the
micromolar range, (Table 4.3) which is consistent with previous reports [14, 17, 36]. The cell-
free and HEK293 expressed proteins had similar binding affinities, further demonstrating that
cell-free produced proteins are functional.
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Figure 4.4. Microscale Thermophoresis Measurements of Purified GPCRs. A) Cell-free
expressed hVN1R1 (o) and the heat-denatured control (x). B) HEK293 expressed hVN1R1 (o) and
the heat-denatured control (x). The non-denatured receptors show typical sigmoidal binding
curves, with plateaus at low and high concentrations. The heat-denatured controls have flat
responses or random amplitudes throughout the ligand titration range. Together, these results
show hVN1R1 is binding carveol. The similar ECso values demonstrate that cell-free produced
receptors function as well as HEK293 expressed receptors. The curves were normalized to the
fraction of bound receptor. Each data point represents the mean of 3 independent experiments;
error bars show the standard deviation. The binding curves were fit to the Hill equation. The
binding results shown are representative of the data from other receptors.
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Table 4.3: Ligand Binding Measurements of Selected GPCRs
Receptor Expression Ligand Measured ECso
Method Used (pM)
mOR103-15 Cell-free Heptanal 2 ± 0.7
mOR174-4 Cell-free Ethyl Vanillin 7 ± 2
mOR174-9 Cell-free Ethyl Vanillin 4.9 3.5
Olfr226 Cell-free 2,4-DNT 86 36
hVN1R1 Cell-free Carveol 6± 2
hVN1R1 HEK293 Carveol 3.5 ± 0.7
4.4 Discussion
This study shows that cell-free membrane protein production is a useful technology for
expressing milligrams of GPCRs. The receptors could be purified to -90% purity using
immunoaffinity chromatography alone. CD measurements on a subset of purified GPCRs
showed that they had the predicted secondary structures, which suggests that they were properly
folded. Microscale thermophoresis indicated that the cell-free-produced GPCRs were functional
by showing that the purified receptors could bind their reported ligands. Comparison of
HEK293 and cell-free expressed proteins suggests that cell-free systems are a practical
alternative to cell-based platforms for producing GPCRs.
Although cell-free production is a mature technology for soluble proteins, very few
membrane proteins have been produced [1-16], largely due to the lack of suitable detergents and
laborious detergent screens. In this study, Brij-35 performed consistently as the optimal
detergent for olfactory-related GPCRs. Previous reports suggest that, while Brij-35 may not be
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optimal for all membrane proteins or GPCRs, the Brij family of detergents may function best
with cell-free membrane protein expression [3, 14]. While the best detergent for protein
production may not be the best detergent for downstream applications, a single detergent
exchange with FC14 is possible without compromising receptor structure and function. Since
FC14 has been used to obtain protein structures [46, 47], it should be possible to couple cell-free
expression with crystal screens or NMR structural studies.
Table 4.4: GPCR Yields in Large-Scale Expression Platforms*
Expression Platform Receptor Yield
E. coli ~0. 15-0.20 mg/L
Yeast ~4 mg/L
Insect Cells ~2mg/L
Mammalian Cells ~1.7-2 mg/L or <1mg/g of cells
Cell-Free ~0.5-1 mg/mL
*Adapted from [48].
In order to accelerate membrane protein structure and function studies, it is vital to
develop simple, straightforward methods of producing sufficient quantities of membrane
proteins. Commercial cell free kits offer an attractive alternative to cell-based systems. In this
study, milligrams of protein could be produced within hours directly from plasmid DNA. These
yields are comparable to those previously reported, and are significantly greater than yields in
other systems (Table 4.4) [48]. Because the materials used here are commercially available, the
necessary reagents are easily and widely obtainable, and results are reproducible. Furthermore,
the produced proteins can be purified quickly using conventional methods, and are amenable to
detergent exchange for downstream applications. Although the 13 GPCRs reported here
represent a small fraction of all receptors, it is the largest number presented in a single study with
a single method. The ability, demonstrated by this study, to produce significant quantities of
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these GPCRs using commercial cell-free systems demonstrates in turn the usefulness of this
technology in the field. Indeed, the critical production bottleneck in membrane protein studies
may potentially be overcome. Structure and function studies of additional GPCRs may be
stimulated and accelerated in the coming years.
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CHAPTER 5
DESIGNER LIPID-LIKE PEPTIDES: A
CLASS OF DETERGENTS FOR
PRODUCING, SOLUBILIZING, AND
STABILIZING FUNCTIONAL
OLFACTORY RECEPTORS
This chapter is an expansion of a manuscript accepted by PLoS ONE, and a manuscript
published by PNAS:
Corin, K., Baaske, P., Ravel, D.B., Song, I., Brown, E., Wang, X., Wienken, C.J., Jerabek-
Willemsen, M., Duhr, S., Braun, D., Luo, Y., & Zhang, S. (2011) Designer lipid-like
peptides: A class of detergents for studying functional olfactory receptors using
commercial cell-free systems. PLoS ONE, (In press).
Wang, X*, Corin, K*, Baaske, P., Wienken, C.J.,Jerabek-Willemsen, M., Duhr, S., Braun,
D., & Zhang, S. (2011) Peptide surfactants for cell-free production offunctional G
protein-coupled receptors. PNAS, doi: 10.1073/pnas.1 018185108.
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5.1 Introduction
Selecting an appropriate detergent is crucial for membrane protein studies, yet is a
daunting task. A bewilderingly large selection of surfactants is available, and the optimal
detergent for a protein must be empirically determined [1]. To further complicate matters,
detergents that are optimal for one application may not be appropriate for others. For example,
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detergents that best solubilize proteins from cell membranes often cause destabilization or
denaturation in the long run. Additionally, detergents appropriate for biochemical assays may
inhibit protein crystallization [1, 2]. Careful screening is necessary, but is a time-consuming and
expensive process. Finding an appropriate detergent has thus become a critical bottleneck not
only for GPCR and other membrane protein studies, but also for designing and producing
membrane proteins for biotechnological devices.
The limitations and problems encountered with traditional detergents highlight the need
for a general class of detergents that can work with diverse membrane proteins. Several attempts
have been made, including the design of amphipathic helical peptides, lipopeptides, amphipols,
and tripod amphiphiles [3-8]. However, these surfactants are expensive, difficult to manufacture,
or heterogeneous. Some, moreover, are ineffective with many proteins, or cannot maintain
proteins soluble and functional for sufficient periods of time.
The Zhang Laboratory at MIT has designed a class of simple peptide surfactants as an
alternative both to traditional detergents and the innovative strategies mentioned above (Figure
5.1). These peptides have a charged hydrophilic head made from one lysine or aspartic acid, and
a 3-6 residue hydrophobic tail. All tail residues are composed of one of the following amino
acids: glycine, alanine, valine, leucine, or isoleucine. Acetylation at the N-terminus, amidation at
the C-terminus, or both, can be used to control the ionic nature of each peptide. This capping
strategy allows the construction of cationic, anionic, and zwitterionic peptides. These peptide
surfactants have defined critical aggregation concentrations (CAC), and form nanostructures
including micelles, nanovesicles and nanotubes [9-13]. They also interact well with lipids to
form monoolein bilayers [14]. More importantly, they have been shown to solubilize and
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stabilize several diverse multi-transmembrane proteins, including Glycerol-3 -phosphate
dehydrogenase [15], photosystem I [16, 17], and a handful of GPCRs [18, 19].
A
C
E
G
B
D
F
H
Figure 5.1. Molecular models of peptide surfactants at neutral pH. A) Ac-AAAAAAD-COOH. B)
Ac-AAAAAAK-CONH 2. C) DAAAAAA-CONH 2. D) KAAAAAA-CONH 2. E) Ac-VVVD-COOH. F) Ac-VVVK-
CONH 2. G) Ac-IIID-COOH. H) Ac-IIIK-CONH 2. 1) Ac-LLLD-COOH. J) Ac-LLLK-CONH 2. Aspartic acid
(D) is negatively charged and lysine (K) is positively charged. The hydrophobic tails of the peptide
surfactants consist of alanine (A), valine (V), isoleucine (I) and leucine (L). Each peptide is -1.5--2.5
nm long, similar in size to biological phospholipids. Color code: green, carbon; red, oxygen; blue,
nitrogen and white, hydrogen.
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The success of using peptide surfactants to stabilize a small number of membrane
proteins suggests that they may be capable of functionally stabilizing a larger number of
receptors. To test this hypothesis, 12 olfactory receptors were expressed in the presence of 10
different peptide surfactants (Figure 5.1) using a cell-free expression system. The peptides'
performance was compared to Brij-35, a common detergent that works best with cell-free GPCR
expression (Chapter 4). All 10 peptides were able to solubilize all 12 ORs, demonstrating their
potential as a class of surfactants for OR and other membrane protein studies.
5.2 Methods
All methods are the same as those reported in Chapter 4, with the following
exceptions.
5.2.1 Peptide Synthesis
The peptides shown in Figure 5.1 were synthesized and purified by CPC Scientific
Inc., CA. The peptides, received in powder form, were dissolved in milli-Q water, sonicated,
and adjusted to a pH value above 7.0 with NaOH or HCl to increase peptide solubility. The
suspension was then filtered through a 0.22 pm filter to remove insoluble particles and
stored at room temperature.
5.2.2 Cell-Free Olfactory Receptor Expression and Purification
The ORs were expressed in the manner described in Chapter 4, with the exception
that peptide surfactants were added directly to the reaction mixture prior to incubation.
The peptides were sonicated for 10 minutes prior to adding them to the reactions. The
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final concentrations of each peptide used are shown in Table 5.1. Because the peptides
elicit a circular dichroism (CD) signal that interferes with and overwhelms the protein
signal, all purifications were performed using FC14. Because protein can be reused after a
CD scan, the same receptor samples were used for CD and thermophoresis measurements.
Table 5.1. Surfactant Peptide Properties and Experimental Concentrations
Peptide Molecular Net Experimental CAC in water
(1-letter code) weight (kDa) charge at Concentration (mM) 1
pH 7.0
Ac-VVVD 472.5 -2 0.625mM 2  2.3
Ac-VVVK-CONH2 484.6 +1 2.5mM 1.6
Ac-IlD 514.6 -2 0.625mM 2  1.0-1.2
Ac-IIIK- CONH2 526.7 +1 0.625mM 0.4-0.5
Ac-LLLD 514.6 -2 2.5mM 1.2
Ac-LLLK- CONH2 526.7 +1 2.5mM 1.2
Ac-AAAAAAD 601.6 -2 1.7 mM 0.3
Ac-AAAAAAK- 613.7 +1 1.6mM 0.2
CONH 2
DAAAAAA- 558.6 0 2.5mM 0.2
CONH 2
KAAAAAA- 571.7 +2 0.5mM 0.3
CONH2
1. CAC-critical aggegation concentration. Two conventional methods, electrical conductivity and
surface tension measurements, were used to determine the CACs of ten peptide surfactants in
water. The peptides typically have 6-fold lower CACs in PBS.
2. Due to peptide solubility, higher concentrations were not possible. However, because the
peptides typically have 6-fold lower CACs in PBS, the concentrations used for all experiments were
estimated to be above their CAC.
5.3 Results
5.3.1 Detergent Screening
Systematic screens were used to assess the ability of peptide surfactants to produce
and solubilize 12 ORs in a commercial E.coli-based cell-free expression system. First, the
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ability of diverse peptides to function as surfactants was tested. Four ORs were selected
and produced in the cell-free system in the presence of all 10 peptides. The soluble and
insoluble protein fractions were compared (Figure 5.2A). The surfactant Brij-35 was used
as a control because Brij-35 is the optimal surfactant for producing ORs in the cell-free
system (Chapter 4). Reactions with no surfactant served as additional controls. Second, the
ability of peptides to solubilize a wide variety of ORs was tested by comparing the solubility
of all 12 ORs in 4 peptide surfactants and Brij-35 (Figure 5.2B).
Western and dot blot analysis was used to compare the soluble and insoluble
protein fractions. Figure 5.2A shows that a surfactant is necessary to solubilize the ORs.
Without surfactant, only -10% of the produced protein is soluble. With a proper
surfactant, up to 95% of the expressed protein becomes soluble. The peptides and Brij-35
maintained similar fractions of ORs soluble. Brij-35 solubilized 63-95% of the expressed
ORs, with most receptors having soluble fractions between 80-90%. The peptides
solubilized 57-93% of the expressed ORs, with most ORs having fractions between 75-90%.
Figure 5.2B shows that the 4 peptide surfactants solubilized -60-90% of all 12 ORs,
suggesting their potential use as a general class of surfactants for additional ORs and
perhaps a wider range of GPCRs and other membrane proteins. Figure 5.2B also suggests
that the peptide properties affect their performance as surfactants. The cationic peptides
(Ac-A6K-CONH2 and Ac-V 3K-CONH2) solubilized a greater percentage of protein than their
anionic counterparts (Ac-A6D-COOH and Ac-V 3D-COOH). Also, peptides with longer
hydrophobic tails yielded higher soluble fractions than peptides with shorter tails (Ac-A6K-
CONH 2 v. Ac-V 3K-CONH2 and Ac-A6D-COOH v. Ac-V 3D-COOH).
127
ALI
n
Fi
ii
*tK0i7 11
*nou#IS
DmOR3 I)
S0~)?)m
1~ ,9p
B
40
Spw 'MkS
OMCAO400
S*CMMO"
Figure 5.2. Olfactory Receptor Solubility in Brij-35 and Peptide Surfactants. Each OR was
expressed in the presence of Brij-35 or a peptide surfactant using a commercial E.coli cell-free
expression system. Upon completion of the reactions, the samples were centrifuged to separate
solubilized receptor from insoluble aggregates. The soluble fraction was removed, and the pellet
was resuspended in an equal volume of buffer. Soluble and precipitated protein samples were
analyzed with Western and dot blots using an anti-rho-tag monoclonal antibody; relative sample
intensities were used to calculate the percentage of solubilized receptor. As controls, reactions with
no peptide or other detergent were assayed. All bars represent the average of two or three
independent experiments. A) The presence of a detergent was necessary to solubilize the GPCRs,
and all of the peptide surfactants were able to solubilize four unique ORs. B) The surfactant
peptides and Brij-35 were able to solubilize similar fractions of protein. Peptides that were
positively charged or had longer tails tended to solubilize higher fractions of receptors.
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5.3.2 Determination of Receptor Yields
The maximum yields of olfactory receptors produced in the presence of the peptide
detergents were estimated by comparing their band intensity to that of a receptor with a known
concentration. Milligram quantities of receptor could be produced, demonstrating that cell-free
synthesis in the presence of peptide detergents is a good alternative for large-scale olfactory
receptor production, and perhaps for others GPCRs as well. However, as with the solubilization
results, the protein yield depended on both the specific receptor and the specific peptide
detergent used (Figure 5.3A). At least 2mg of hOR17-210 and mOR33-1 could be produced in a
10ml E.coli cell-free reaction with at least 5 of the peptide detergents. The peptide Ac-A6D-OH
yielded the largest amount: ~4.8mg of mOR103-15 per 1 0ml reaction. Six other peptides were
able to produce at least -2.5mg for at least one OR: Ac-A6K-NH2, Ac-13D-OH, Ac-L3D-OH, Ac-
L3K-NH 2, Ac-V3D-OH, and Ac-V3K-NH2. Overall, at least 2mg of most receptors could be
synthesized in a 10ml reaction in the presence of at least one of the peptide detergents. These
amounts were comparable to those that could be obtained using Brij-35 (Figure 5.3B).
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AFigure 5.3. Detergent Peptides Can Yield Milligram Quantities of Solubilized Olfactory
Receptors. The total receptor yield is dependent on the peptide used. A) The maximum expected
yields of solubilized monomer for 6 of the receptors in the presence of each peptide. To determine
the expected yields, solubilized receptor and protein with a known concentration were compared
on a Western blot. The relative intensities of the known protein sample and the test samples were
used to calculate the maximum receptor yields. B) The maximum yield of the monomeric form of
some tested olfactory receptors expected in a 10ml reaction. Only results from the most effective
detergent peptide are shown. The total protein yield is dependent on the peptide detergent used.
These results are compared to the yields of receptors made in Brij-35. In most cases, the yields are
comparable. For two receptors, Brij-35 resulted in more expressed protein, and for one receptor a
peptide resulted in more.
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5.3.3 Olfactory Receptor Purification and Purity Analysis
Four olfactory receptors were selected for larger scale expression and purification for
structural and functional analysis. The olfactory receptors mOR103-15, mOR174-4, mOR174-9,
and Olfr226 were expressed using Brij-35 or a peptide detergent, and purified using the rholD4
monoclonal antibody. The purifications were performed in the presence of fos-choline 14
(FC 14) because it has been shown to be the preferred detergent for olfactory receptor purification
[20-22], and because a common buffer for the Brij-35- and peptide-produced receptors allows for
direct comparison between the two samples. Moreover, a detergent exchange was necessary in
order to carry out subsequent analyses, as the peptides elicit signals that are difficult to
distinguish from the receptor signals. Because a simple detergent exchange is unlikely to re-fold
misfolded receptors, the structures of the olfactory receptors initially produced in Brij-35 or a
peptide should not be positively affected by the change to FC14.
The purified receptors were analyzed on a gel (Figure 5.4). The olfactory receptors
produced in both the Brij-35 and peptide detergents were the same size, and exhibited the
expected monomeric and dimeric bands. These results suggest that the peptide detergents do not
interfere with full-length cell-free protein expression. They further suggest that the peptide
detergents do not interfere with proper receptor folding or structure, as the expressed protein
shows the tendency to dimerize. Silver staining showed that receptors expressed in Brij-35 could
be purified up to ~90% purity, while receptors expressed in a peptide could be purified up to
>80% purity, using immunoaffinity chromatography alone. The lower purity of the peptide-
produced samples is due primarily to the presence of 2 bands around 60 and 8OkDa. It is
possible that these bands are impurities in the sample, or result from ORs aggregating
during the gel electrophoresis. However, since the peptides can form various mesoscale
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structures, it is possible that the extra bands represent different states of the peptide-OR
complexes.
50k
30k
Figure 5.4. Silver Stain of Four Purified Olfactory Receptors Produced in Either Brij-35 or a
Peptide. Lane 1: mOR103-15 produced in Brij-35. Lane 2: mOR103-15 produced in Ac-V3K-
CONH 2. Lane 3: mOR174-4 produced in Brij-35. Lane 4: mOR174-4 produced in Ac-V 3K-CONH 2.
Lane 5: mOR174-9 produced in Brij-35. Lane 6: mOR174-9 produced in Ac-A6D-OH. Lane 7:
01fr226 produced in Brij-35. Lane 8: Olfr226 produced in Ac-A6K-CONH 2.The Brij-35 and peptide-
produced samples have similar purities. Also, all of the ORs are the same size show the same
tendency to dimerize. This indicates that both types of surfactants function comparably, and that
the peptides do not interfere with full-length protein translation, or proper receptor folding or
function.
5.3.4 Secondary Structural Analysis Using Circular Dichroism
Circular dichroism was used to assess the secondary structure of the 4 purified olfactory
receptors. The purification and CD analyses of olfactory receptors were performed in FC-14
because the peptides themselves have strong CD signals that interfere with and overwhelm
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the receptor signals. Figure 5.5 directly compares the CD spectra of ORs produced in either
Brij-35 or a peptide detergent. All purified receptors have characteristic ct-helical spectra, with
signature valleys at 220 nm and 208 nm. Because GPCRs have seven transmembrane a-helical
domains, these spectra indicate that the receptors are properly folded. Moreover, the nearly
superimposed spectra for ORs produced in Brij-35 or a peptide surfactant indicate that the
peptide surfactants are able to structurally stabilize these olfactory receptors equally as well as
traditional surfactants.
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Figure 5.5 CD spectra of Brij-35 and Peptide Surfactant-Produced Olfactory Receptors. A)
Olfr226, B) mOR174-4, C) mOR174-9, and D) mOR103-15. All eight samples have characteristic
secondary ct-helical spectra, suggesting that the receptors are properly folded. The near overlap of
the peptide and detergent CD curves suggests that, for olfactory receptors, the peptides function as
detergents as effectively as traditional detergents.
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5.3.5 Ligand-Binding Analysis Using Microscale Thermophoresis
Microscale thermophoresis was used to determine whether the expressed and purified
proteins were functional. This approach is based on the ligand binding-induced change in
movement of molecules along a temperature gradient [23, 24], and is capable of detecting
interactions with ligands as small as calcium ions [25]. Because olfactory receptors are larger
than 35kDa and their ligands are smaller than 300Da, it was necessary to use thermophoresis to
detect ligand binding instead of less sensitive methods like SPR or quartz crystal microbalance.
All 8 receptors used with CD were analyzed with their known odorants (Table 4.1). Boiled
receptors were used as controls.
Figure 5.6 and Table 5.2 show the results of the Brij-35- and peptide surfactant-
solubilized ORs, and their boiled controls. All of the protein samples exhibited a typical
sigmoidal binding curve. In contrast, the boiled controls had random amplitudes
throughout the ligand titration range. These results indicate that that all of the ORs bound
their respective odorants. The large noise in the boiled controls is probably due to the
presence of protein aggregates of different size, and hence various diffusive and
thermophoretic properties. Olfr226 produced in peptide exhibited a significantly higher
affinity for its ligand than receptor produced in Brij-35. The other ORs had similar binding
affinities in both types of surfactants. These results show that both classes of detergents are
able to aid in the production and solubilization of functional olfactory receptors, and that
peptides may confer more functional stability to some solubilized receptors. The measured
ECso value for each tested olfactory receptor is in the micromolar range, which is consistent
with previous reports [21, 22].
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Figure 5.6. Binding of Olfactory Receptor Olfr226 to its Ligand 2,4-DNT: A) Olfr226 produced
in Brij-35, B) Olfr226 produced in Ac-A6K-NH2, C) Olfr226 produced in Brij-35 and boiled, and D)
Olfr226 produced in Ac-A6K-NH2 and boiled. Olfactory receptors produced in Brij-35 or a peptide
surfactant exhibit typical sigmoidal binding curves. There is one plateau at low concentrations and
another at high concentrations, while the boiled controls have no plateaus. This suggests that the
thermophoresis signals are measuring ligand binding. All curves were normalized to the fraction of
bound receptor. Open circles show the mean measurements from 3 experiments; the lines through
the points are the best-fit curves using the Hill equation to obtain the half maximal effective
concentration ECso. The binding results shown here are representative of the data from all four OR
samples.
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Table 5.2. Ligand Binding Affinities For Peptide-
Olfactory Receptors
*This measurement was obtained at a longer time (25s vs. 15s) and
2.5V) than the other measurements.
and Brij-35- Produced
lower IR-laser power (1.5V v.
5.4 Discussion
This study showed that short peptide detergents solubilized and functionally
stabilized cell-free produced olfactory receptors equally as well as the detergent Brij-35.
All of the tested peptide detergents were able to solubilize all of the tested olfactory
receptors. Soluble olfactory receptor fractions were as high as 93%. We previously
reported lower solubilities for hOR17-210 and mOR103-15 in the presence of some
peptides [19]. This difference in solubility is probably due to differences in the peptide
batches, or the dynamic nature of the peptides. Previous reports have noted the peptides'
ability to form various mesoscale structures, and to change between structures over time.
It is probable that specific structures are better able to solubilize the expressed receptors,
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Receptor Surfactant Used Ligand Measured EC5O
(RM)
mOR103-15 Brij-35 Heptanal 2 ± 0.7
mOR103-15 Ac-V3D-OH Heptanal 0.9 ± 0.2*
mOR174-4 Brij-35 Ethyl Vanillin 7 ± 2
mOR174-4 Ac-V 3D-OH Ethyl Vanillin 4 ± 2
mOR174-9 Brij-35 Ethyl Vanillin 4.9 ± 3.5
mOR174-9 Ac-A6D-OH Ethyl Vanillin 5.1 ± 2
Olfr226 Brij-35 2,4-DNT 86± 36
1Olfr226 Ac-A6K-NH2 2,4-DNT 3 ± 1.6
and more research needs to be done to elucidate these effects. However, the comparable
results between the peptides and Brij-35 for 12 olfactory receptors reported here
demonstrates their potential to be used as detergents for membrane protein studies.
The results in this study show that the efficacy of solubilization primarily depends
on the peptide detergent properties. Figure 5.2B shows that the cationic peptides usually
solubilized a greater fraction of expressed protein than their anionic counterparts. This
effect was more pronounced for the longer peptides (12 out of 12 olfactory receptors with
Ac-A 6K-NH2 and Ac-A6D-OH) than for the shorter peptides (10 out of 12 olfactory receptors
with Ac-V3K-NH2 and Ac-V3D-OH). Figure 5.2A indicates that this effect may depend on
the specific receptor. The receptors hOR17-210 and mOR171-2 were consistently more
soluble in cationic peptides, while the receptors mOR103-15 and mOR106-13 were often
more soluble in anionic peptides. Because mOR103-15 and mOR106-13 had greater
solubility in the more hydrophobic anionic peptides (leucine and isoleucine tails), it is
probable that the tail composition can alter tendencies caused by the head group
properties. Additionally, peptides with longer hydrophobic tails typically had higher
soluble fractions than those with the same charge but shorter tails (10 receptors for the
cationic peptides, 9 for the anionic) (Figure 5.2B). Figure 5.3A further suggests that
subtle changes in the residue order may affect how the peptides interact with the olfactory
receptors expression. Although composed of the same amino acids, Ac-A6D-OH yielded
significantly more protein than Ac-DA6-NH2. A similar result was observed with most
tested olfactory receptors with Ac-A6K-NH2 and Ac-KA6-NH2. These results further indicate
the peptide charge or ionic character can greatly affect olfactory receptor solubility or
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expression. Additional experiments will be needed to fully characterize and understand
the effects of peptide properties on olfactory receptor solubilization and production.
CD and microscale thermophoresis demonstrated that peptide- and Brij-35-
produced ORs had similar structures and binding affinities. All of the purified ORs had
characteristic a-helical spectra, which is expected for the 7-transmembrane helix members
of the GPCR family. Moreover, the spectra of the Brij-35 and peptide-purified ORs nearly
overlapped. Because even small changes in secondary structure are detectable using CD,
these spectra indicate that the peptides were able to aid in the proper folding of expressed
ORs equally as well as Brij-35. Slight differences in the spectra are probably the result of
differences in sample purity, or the presence of residual peptides after the purification
process. The peptide-produced proteins had similar or higher-affinity binding constants
than the Brij-3 5-produced proteins. The higher binding constant indicates tighter binding,
which could be a result of a more stable receptor conformation. This suggests that the
peptide surfactants may be a useful tool in crystallizing GPCRs, and may also be able to aid
in the development of GPCR-based technological devices. Further studies are necessary to
determine the lifetime of a functional receptor in a surfactant peptide. However, the
results reported here, as well as previous studies [15-19], indicate that that the peptides
may be able to fulfill just such a function, perhaps better than many traditional detergents.
Furthermore, these findings are particularly important because they suggest that the
peptides are a general class of detergents that can be used with cell-free expression
methods. Although cell-free production is a mature technology for soluble proteins [26-
28], very few membrane proteins have been produced through this technique, and even
then only through laborious surfactant screens [22, 29-32]. The methods reported here
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may help accelerate the production of many more membrane proteins for structural
studies and biotechnological advancements.
The peptide surfactants described here may be useful for diverse membrane protein
studies. They function comparably to traditional surfactants, and offer several advantages
over other novel surfactants. Their properties are similar to commonly used detergents,
they can be systematically designed and economically produced at high purity, and they
remain stable for long periods of time. The ability of every tested peptide to solubilize 12
ORs from three different species, and of 3 peptides to functionally stabilize 4 ORs further
suggests that they may be a general class of surfactants capable of functionally solubilizing
a wider range membrane proteins. Further studies are needed to characterize surfactant
peptide property effects on membrane proteins; it may be possible to rationally design a
surfactant optimal for a given protein. Future studies are also needed to analyze the long-
term stability of membrane proteins solubilized in the peptide surfactants. However, this
study suggests that peptide surfactants are promising for membrane protein studies, that
they could lead to a better understanding of olfactory receptors and other GPCRs, and also
could be used in the design and fabrication of diverse OR-based biotechnological devices.
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CHAPTER 6
EVALUATION OF THE EFFECT OF
SURFACTANT PEPTIDE PHYSICAL
AND CHEMICAL PROPERTIES ON
OLFACTORY RECEPTOR SOLUBILITY
6.1 Introduction
Chapter 5 demonstrates the usefulness of peptides as surfactants for GPCR studies.
The data in Figure 5.2 further suggests that the efficacy of solubilization depends in part
on the peptide surfactant properties. Figure 5.2B shows that the cationic peptides usually
solubilized a greater fraction of expressed protein than their anionic counterparts. This
effect was more pronounced for the longer peptides (12 out of 12 ORs with Ac-A6K-NH2
and Ac-A6D-OH) than for the shorter peptides (10 out of 12 ORs with Ac-V3K-NH2 and Ac-
V3D-OH). Figure 5.2A suggests that this effect may depend on the specific receptor. The
receptors hOR17-210 and mOR171-2 were consistently more soluble in cationic peptides,
while the receptors mOR103-15 and mOR106-13 were often more soluble in anionic
peptides. Because mOR103-15 and mOR106-13 had greater solubility in the more
hydrophobic anionic peptides (leucine and isoleucine tails), it is reasonable to hypothesize
that the tail composition can alter tendencies caused by the head group properties.
Additionally, peptides with longer hydrophobic tails typically had higher soluble fractions
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than those with the same charge but shorter tails (10 receptors for the cationic peptides, 9
for the anionic) (Figure 5.2B). Figure 5.3A further suggests that subtle changes in the
residue order may affect how the peptides interact with OR expression. Although
composed of the same amino acids, Ac-A6D-OH yielded significantly more protein than Ac-
DA6-NH2. A similar result was observed with most ORs tested with Ac-A6K-NH2 and Ac-
KA6- NH2. These results further suggest that the peptide charge or ionic character can
greatly affect OR solubility or expression.
This study examined the hypothesis that peptide surfactant properties affect GPCR
solubility. A set of peptides was designed to test the following potential variables: tail
length, tail hydrophobicity, peptide flexibility, residue volume, and head group charge. Six
different GPCRs were expressed in the set of peptides, and the insoluble and soluble
protein fractions were compared. Surprisingly, the hydrophobicity, flexibility, and volume
of the tail residues had no effect on GPCR expression or solubility. Moreover, despite the
suggestive results reported above, the tail length and head group charge had negligible
affects on GPCR solubility. This data suggests that although some physical properties may
affect the peptide surfactants ability to function as detergents, these effects are not
significant enough to warrant the careful design of peptides for a specific receptor. This
further suggests that these simple peptides could be broadly useful as a general class of
mild detergents for membrane protein studies.
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6.2 Methods
6.2.1 Amino Acid Selection
Two sets of peptides were constructed. The first was designed to test the variables
of tail hydrophobicity, flexibility, and residue volume. The second tested the variables of
tail length and head group charge.
The first set of peptides consisted of Ac-G3K-NH2, Ac-A3K- NH2, Ac-V3K-NH2, Ac-13K-
NH2, and Ac-L3K- NH2 (Table 6.1). The head group amino acid and tail length were held
constant, while the residues comprising the tail were varied. All 5 peptides were needed in
order to simultaneously test the effects of hydrophobicity, flexibility, and volume because
some of the variables are difficult to decouple. In general, as the volume of the side chain
increases, the hydrophobicity and rigidity also increase (Table 6.1). However, because of
the beta-branching of its residue side chain, isoleucine is significantly more flexible than
leucine, even though both residues have the same composition and volume (Figure 5.1,
Table 6.1) [1]. Moreover, although it has a larger volume, isoleucine is also significantly
more flexible than the beta-branched valine. Thus, if residue volume is a critical variable,
GPCR solubility should increase or decrease as the tail residue is changed from glycine to
isoleucine, but should be the same for leucine and isoleucine. However, if tail flexibility is a
critical parameter, solubility in isoleucine should be comparable to alanine (Table 6.1).
Although hydrophobicity generally increases as the residue volume increases, valine has a
higher hydrophobicity than leucine, and a similar hydrophobicity to isoleucine [2], possibly
due to the bulk of the side chain residing closer to the backbone, thus shielding it from
aqueous solution (Table 6.1). Thus, if hydrophobicity is a critical parameter, GPCR
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solubility should increase or decrease as the residue volume increases, with the exception
that solubility in valine should most similar to that in isoleucine.
The second set of peptides consisted of two subsets. The first subset included Ac-
A3K-NH2, Ac-A4K-NH2, Ac-AsK-NH2, Ac-A 6K-NH2, while the second subset included Ac-A4D-
OH, Ac-AsD-OH, and Ac-A 6D-OH. Within each subset the tail length varied, while all other
parameters remained constant. Data from the two subsets were compared in order to
examine the importance of head group charge. The peptide Ac-A3K-NHZ was included in
the first subset as a control, so that the data from all of the peptide sets could be compared.
Data from all of the peptides should elucidate not only which parameters affect solubility,
but also their relative importance.
All other methods are as described in Chapters 4 and 5.
Table 6.1. Amino Acid Properties
Amino Acid Volume (A3) [3] Hydrophobicity Flexibility
Index [2] (106 S1) [1]
Glycine 60.1 -0.4 39
Alanine 88.6 1.8 18
Valine 140.0 4.2 3
Leucine 166.7 3.8 2.3
Isoleucine 166.7 4.5 10
6.3 Results
6.3.1 Effects of Residue Hydrophobicity, Flexibility, and Volume
The receptors mOR33-1, hOR17-210, mOR103-15, mOR174-4, mOR106-13, and
Olfr226 were tested with the first set of peptides. Figure 6.1 shows the solubility of each
receptor in each peptide. Surprisingly, no difference in solubility was observed for any
given receptor in any of the peptides. Because hydrophobicity of the tail influences its
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tendency to interact with the GPCR, we would expect an optimal hydrophobicity to exist for
a given head group. If the surfactant isn't hydrophobic enough, it shouldn't be able to
sufficiently shield the transmembrane segments of the expressed protein from aqueous
solution. If the surfactant tail is too hydrophobic, it might not be able to form micelles
capable of solubilizing the protein, and might instead form peptide aggregates that
precipitate out of solution. However, it is possible that hydrophobicity is an important
parameter in general, but that differences in the peptides are not sufficient to yield
observable results within the range of parameters tested. Similarly, one could expect
flexibility to be an important parameter, as a flexible surfactant may be better able to mold
itself to the contours of the expressed GPCR. However, it is possible that flexibility is an
important parameter affecting GPCR solubility. Since the peptide tails were only 3 amino
acids long, differences in their flexibility may have been negligible. It is possible that
differences in solubility may be observed with longer tails. Because no differences were
observed in these six receptors, additional receptors were not tested.
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Figure 6.1: Peptide Volume, Flexibility, and Hydrophobicity Do Not Affect GPCR Solubility.
The solubility of 6 different ORs was examined in peptides with different tail compositions. These
tails had different volumes, flexibilities and hydrophobicities. The tail length and head group
remained constant. All solubilities were normalized to the peptide Ac-A 3K-NH 2, which was defined
to have a relative solubility of 1. No significant differences in OR solubility were observed across
the different peptides.
6.3.2 Effects of Peptide Length and Head Group Properties
The same 6 GPCRs were tested with the second set of peptides. Figure 6.2A shows
that solubility tends to increase as the tail length increases for positively charged peptides.
In contrast, Figure 6.2B shows that solubility for half of the GPCRs tends to decrease with
increasing tail length for negatively charged peptides. However, the reverse trend was
observed for hOR17-210 and mOR103-15, while no trend was observed for 01fr226.
Figure 6.2C shows that the cationic peptides tended to solubilize a greater amount of
receptor than anion peptides, and that this effect was more pronounced as the tail length
increased. This behavior is similar to that of traditional detergents, in that tail length and
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head group charge affect protein stability. In general, detergents with longer tails are
better at stabilizing proteins, while detergents with larger head groups are more soluble [4,
5, Table 1.2]. For the detergents with a lysine head, the increase in solubility with
increasing tail length likely reflects the ability of the longer tail to better stabilize and hence
solubilize the proteins. The different trend observed with the peptides with an aspartic
acid head may reflect the difference in the size of the head group. Lysine is larger, and
perhaps is better at keeping the peptide micelles soluble. It may also promote the
formation of larger micelles: steric hindrance of the head group may make micelle
formation of shorter peptides less favorable. Because the tighter radius of curvature can
provide a harsh environment for membrane proteins, their solubility may increase as the
micelle size increases. Indeed, it's likely that the ratio between the head group size and tail
size may determine whether a particular peptide forms micelles optimal for GPCR
solubilization. Table 6.2 shows that these ratios are similar for Ac-A6K-NH2 and Ac-A4D-
OH, and that they either increase or decrease away from these two points. Because these
two peptides usually produced the most soluble receptor, these ratios strongly suggest that
an optimal mechanical configuration exists. Indeed, the ratio between the head and tail
sizes may indicate the tail length likely to result in optimal micelle packing for GPCR
studies for a given head group, and any given amino acid used for the tail. However, Figure
6.2C further suggests that a peptide surfactants' head group properties will affect its
efficacy once its geometry has been optimized.
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Table 6.2. Size Ratios Between Peptide Surfactant Heads and Tails
Peptide Surfactant Ratio of Ratio of
Head Group Volume: Head Group Volume:
Tail Length Tail Volume
Ac-A 3K-NH2 9.5 0.64
Ac-A4K-NH2 7.6 0.48
Ac-AsK-NH2 6.3 0.38
Ac-A 6K-NH2 5.4 0.32
Ac-A4D-OH 5.0 0.32
Ac-AsD-OH 4.1 0.25
Ac-A6D-OH 3.6 0.21
All together, the data shows that solubility increases with tail length with the
positively charged peptides, and tends to decrease with the negatively charged peptides.
The peptide charge is unlikely to be an important factor independently of tail length. If this
were the case, the same trends would be expected in both subsets of peptides, with one set
consistently showing greater solubility at each tail length. However, it should be noted that
the differences in solubility among all of the tested peptides are slight, and most show no
statistically significant differences. This contrasts greatly with the results observed with
Brij-35, which was 4-5 times better than the next best detergent. Thus, although tail length
and head group size do affect peptide solubility, they are not critical factors of
consideration.
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Figure 6.2. Peptide Tail Length and Head Group Composition Negligibly Affect OR Solubility.
A) Peptides with a cationic head group and tails varying in length between 3 to 6 amino acids were
tested with six ORs. B) Peptides with an anionic head group and tails varying in length between 4 to
6 amino acids were tested with the same set of ORs. C) Comparison of long and short cationic and
anionic peptides. When the head group is positively charged, solubility increases with increasing
tail length. When the head group is negatively charged, the solubility either increases or decreases
with increasing tail length, and the specific trend depends on the receptor. Cationic peptides tend
to solubilize a greater percentage of receptor than their anionic counterparts, and this effect is
more pronounced as the tail length increases. However, differences in solubility among all of the
samples are small. In A) and B), the data was normalized to the shortest peptide (Ac-A3 K-NH2 and
Ac-A4D-OH, respectively). In C), the data was normalized to Ac-A3 K-NH2 .
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6.4 Discussion
This study indicates that the length of the peptide surfactant tail and the size of the
head group can affect GPCR solubility. When the head group was composed of lysine, a
residue with a large side chain, GPCR solubility tended to increase with tail length. In
contrast, when the head group was composed of aspartic acid, a residue with a smaller side
chain, no common trend was observed. Two of the GPCRs were more soluble as the tail
length increased, while three were less soluble and one showed no difference. The
different trends observed among the peptides with lysine or aspartic acid heads are
unlikely to solely result from the head group charge. If the charge was a critical
independent parameter, both sets should exhibit similar trends as the tail length is varied,
with one subset consistently showing higher solubility. Instead, different solubilities were
only consistently observed when the tail length was 6 residues long.
Surprisingly, the hydrophobicity, volume, or flexibility of the tail did not affect
peptide solubility. Although the tested peptides had three-amino acid tails, the results in
Figure 6.2 suggest that this short length is not masking any effects. Longer peptides are
more flexible due to the greater number of potential conformations, and are more
hydrophobic. It is thus possible that the effect of these parameters on GPCR solubility will
not become apparent until the peptides have reached a critical length. However, both Ac-
A3K-NH2 and Ac-A 6K-NH2 have comparable solubilities, suggesting this is not the case. All
of the tested peptides are 2-3nm in length, which is similar to traditional detergents. It is
not practical to greatly increase the length of the peptides, as this would likely result in a
larger "belt" around the solubilized GPCR, which would inhibit protein-protein contacts in a
crystal lattice. An increase in peptide length would also decrease their solubility, making
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them more difficult to handle. Thus, the parameters of hydrophobicity, volume, and
flexibility are not important for GPCR solubility at the length scales that are biologically or
experimentally relevant.
The peptide batch or tendancy to spontaneously form nanostructures may affect the
peptides' ability to solubilize GPCRs. In Chapter 5, solubilities as high as 93% were
observed, while solubilities in this Chapter were, on average, lower for each tested GPCR
(50-85%; the data is not shown). Different batches of peptides were used for the two
studies. This indicates that the manufacturing process, minute impurities, or small
variations in the solubilization of the lyophilized peptides may affect their ability to
perform as surfactants. Also, several studies have reported that the peptides form dynamic
structures, switching from micelles to rods or other structures [6-10]. It is probable that
GPCRs are more soluble in some structures than in others. It was not possible within the
scope of the present study to simultaneously evaluate the peptide microstructure and
GPCR solubility.
As the data in Chapter 5 suggested, the peptide length and head group charge do
affect GPCR solubility. However, Figures 6.1 and 6.2 demonstrate that the effect of these
variables is not significant The ratio of soluble GPCRs in Ac-A6K-NH2and Ac-A3K-NH2was
between -1.2-1.3, and these ratios were the largest observed among all of the peptides.
This indicates that all of the peptides function comparably as detergents. In contrast, Brij-
35 and Brij-58 were 4-5 times better than the next best detergents. This stark difference
suggests that the researcher may decide to use the peptide that is easiest to produce, or
that is most compatible with the desired experiments.
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CHAPTER 7
IN VITRO MUTATIONAL ANALYSIS
OF THE OLFACTORY LIGAND
BINDING POCKET
7.1 Introduction
In order to understand olfaction at the molecular level, as well as rationally design
artificial noses, the odorant binding pocket in olfactory-related receptors must be precisely
determined. Interactions between specific residues, or even atoms, on receptors and their
ligands uniquely determine each receptor's function. For example, the rat 17 olfactory
receptor preferentially binds octanal. A valine to isoleucine switch in the mouse 17
ortholog results in preferential binding to heptanal [1]. The human receptor hOR912-13 is
inactive even when a nonsense mutation resulting in premature truncation is corrected,
while the mouse ortholog strongly binds ketones [2]. Computational analyses indicate that
replacing a glycine with a serine in the predicted hOR912-13 binding site should allow
ligands to form a critical hydrogen bond, and thereby restore the receptor's function [3].
Similarly, 17 out of 18 residues interacting with the ligand eticlopride are identical in the
dopamine D2 and D3 receptors. Modeling studies suggest that subtle differences in the
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backbone conformation or residue packing of these receptors can alter their ligand
selectivity, even when their binding pockets are nearly identical [4].
Although the detailed structure of the binding pocket in olfactory-related receptors
has not been precisely elucidated, its general location is known. Hydropathy plots,
sequence alignments, and residue helix-forming tendencies can be used to predict the
transmembrane regions. Crystal structures of 6 GPCRs and mutational studies confirm that
the ligand-binding domain is in the pocket of the barrel formed by the transmembrane
helices [4-12]. Moreover, alignments of olfactory receptor protein sequences show that
specific regions in the transmembrane segments are highly variable, while other sections of
the receptors are highly conserved. Several groups of researchers have hypothesized that
these variable regions include the binding pocket residues, and it is this variability that
allows olfactory receptors to detect an extraordinary range of odors [13-16]. Additional
studies indicate that the second extracellular loop may also be involved in ligand binding
[14, 17].
There have been extensive modeling and simulation analyses of the binding of olfactory
receptors with their odorants [18-25], but only 3 experimental mutagenesis assays [10, 11,
26]. These mutagenesis experiments were performed in cells with calcium influx assays.
No biochemical, biophysical or structural studies have been performed on the actual
receptors due to the difficulty of producing and purifying them in sufficient quantities. The
methods described in Chapters 2 and 4 have overcome this crucial limitation. The ability to
work in a cell-free system allows many mutants to be quickly and simultaneously screened.
Promising mutants can then be selected, and their activity can be evaluated in HEK293
cells. It is now possible to experimentally verify or discount previous simulations, as well
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as explore critical binding sites in multiple ORs. Indeed, it should now be possible to
determine whether certain residues or alignment positions are conserved in the majority of
OR binding sites.
7.2 Methods
7.2.1 Rationale for Receptor Choice
The receptor mOR103-15 was chosen for mutational experiments because it was a
receptor with one of the highest cell-free expression yields, and because several groups of
researchers have performed simulations to determine key residues involved in binding.
However, no experimental data has yet been generated. Since no OR crystal structure
exists, the actual binding site residues remain unknown. The simulations thus give a
starting point, and the results described here should also indicate how effective various
models are at predicting critical residues in OR binding sites. This also forms a basis that
can be expanded to other ORs.
7.2.2 Rationale for Residue Choice
Two approaches were used to predict residues in the ligand-binding pocket (Figure
7.1). 1) Residues were chosen if they were implicated by multiple computational analyses
specific for mOR103-15. 2) A sequence alignment of mOR103-15 with the ORs analyzed in
Chapter 4, the ORs published by [10, 15, 18-24], and the GPCRs with known structures was
performed. Residue positions that mutational or computational studies suggested may
form the pocket were examined. Residues were chosen for mutational analysis if their
position was involved in binding in multiple studies, or if a position reported in a single
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study belonged to a residue with potentially critical or highly conserved properties. To test
whether the chosen residues were involved in ligand binding, they were mutated to
residues with opposite physical or chemical properties.
Several independent simulations indicate that K164 is a critical residue involved in
hydrogen bonding and ligand recognition, and that D204 is a residue that may participate
in this interaction [18, 21, 19]. Because any ligand binding interactions would be due to
their charged, hydrophilic nature, these residues were mutated to the hydrophobic residue
leucine. Some reports indicate that the ligand binding pocket is lined with hydrophobic
residues like F262 whose volume limits the size of the entering odorants [25]. To preserve
the relatively hydrophobic nature of this residue while changing its shape and flexibility,
this residue was also changed to leucine. The residues L216 and F256 have been
implicated in binding in other ORs. The residue F256 is relatively conserved throughout
the OR family, while L216 is in a hypervariable region. Mutational analysis has shown that
that both residues are important for ligand binding in mOR174-9 [10]. Hydrophobic
binding pocket residues probably interact with odorants through hydrophobic or van der
Waals interactions. Because the latter in particular is sensitive to distance, the residue
L216 was changed to the smaller residue valine. Because a phenylalanine-to-leucine
substitution severely diminished binding activity in mOR174-9, this strategy was also
employed with F256: this residue was mutated to leucine.
It has been proposed that metal binding is important for odorant receptor
activation. The conserved histidine H181 has been proposed as a metal-binding site [17].
This histidine is located in a conserved motif common to the OR family, suggesting that this
sequence may impart a specific olfactory function. When expressed as an independent
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peptide, this 5-residue motif can bind copper and zinc ions, and this binding induces an a-
helical conformation [17]. Metal ions are present in the buffers used to synthesize and
purify the olfactory receptors. To test whether this residue might be involved in ligand
recognition, and to abolish potential metal-coordinating abilities, it was mutated to a
leucine.
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Figure 7.1. Sequence and 2D-Topology of mOR103-15. A) The sequence of the native mouse
olfactory receptor mOR103-15. The proposed mutation sites are highlighted in red, the
hypothesized metal-binding region is highlighted in blue, the 7 predicted transmembrane domains
are underlined, and the rho1D4 epitope used for purification and GSSG linker are highlighted in
green. B) The two-dimensional topology of mOR103-15 showing the predicted transmembrane
regions and ligand-binding sites (red). The snake plot was generated using [33].
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7.2.3 Gene Design, and Receptor Expression and Analysis
Six single-amino acid variants of mOR103-15 were designed with the mutations
described above. The genes were synthesized by GeneArt, and subcloned into the pIVex2.3
vector using the NcoI and XhoI restriction sites. The protocols for expressing and purifying
receptors are described in Chapter 4, as well as the methodologies used to assay their secondary
structure and ligand-binding ability.
7.3 Results
7.3.1 Protein Expression and Purification
The six mOR103-15 mutants and native protein were expressed in cell-free
reactions, and purified using immunoaffinity chromatography. The purified samples were
analyzed on a western blot and silver stain (Figure 7.2). Both gels showed bands that ran
at the expected monomer and dimer sizes. The western blot confirmed the identity of the
proteins, while the silver stain showed that they could be purified to the same level.
Because all of the mutants ran at the same size as the native protein, and they all showed
the same tendency to dimerize, their global structure and backbone conformation were
probably not compromised as a result of the mutations. Instead, any conformational
changes that may affect receptor function are probably more localized.
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Figure 7.2: Silver Stain of the Native and Mutant mOR103-15 Receptors. Lane 1: mOR103-15,
Lane 2: mOR103-15 K164L, Lane 3: mOR103-15 H181L, Lane 4: mOR103-15 D204L, Lane 5:
mOR103-15 L216V, Lane 6: mOR103-15 F256L, Lane 7: mOR103-15 F262L. All of the receptors are
the same size and show the same tendency to dimerize. They can also be purified to the same level
of purity.
7.3.2 Secondary Structure Analysis
Circular dichroism was used to analyze the secondary structure of the purified
mutants and native protein. All of the samples had characteristic a-helical spectra,
indicating that they were properly folded (Figure 7.3). Moreover, the spectra of the native
and mutant proteins nearly overlapped, indicating that they were folded in the same
manner. This data and the spectrum of mOR103-15 expressed without detergent further
suggest that the mutations do not result in misfolded receptors. Lack of receptor function
could be due to either improper protein folding, or a physical or chemical change in key
binding-pocket residues. The mutant CD spectra and gel images suggest that the receptors
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are folded into 7 transmembrane a-helices, and that any changes observed in ligand
binding result from local disturbances introduced through the mutations.
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Figure 7.3: Circular Dichroism Spectra of Native and Mutant mOR103-15. The native receptor
and the L216V mutant have overlapping spectra that are characteristic of an c-helical secondary
structure, while the native receptor made without detergent has a spectrum reminiscent of a
random coil. This suggests that the native and mutant receptors made with detergent are properly
folded, and that the mutation does not affect protein folding. The spectrum of mOR103-15 L216V is
characteristic for all of the mutants.
7.3.3 Ligand Binding Analysis
The same receptor samples that were analyzed using circular dichroism were also
analyzed using microscale thermophoresis. As a control, a boiled sample of mOR103-15
was also analyzed.
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The native mOR103-15 and boiled control exhibited the same binding behavior
observed in Chapter 4. The native receptor bound its ligand heptanal with an ECso of
1.4M, while the denatured sample did not exhibit any binding (Figure 7.4). The similar
binding behavior in two different mOR103-15 samples reinforces the conclusion that the
measurements are detecting binding between the receptor and its ligand.
Two of the mutants were able to bind heptanal, while no binding was seen in others
(Figure 7.4, Table 7.1). The mutant D204L bound heptanal with an ECso similar to that of
the native protein, indicating that this residue is not critical for ligand binding. The mutant
F262L was also able to bind heptanal, albeit with an affinity that was an order of magnitude
lower. This significant difference suggests that this residue is involved in binding the
ligand, though perhaps indirectly. All ligand-binding was abolished in the mutants K164L,
F256L, H181L, and L216V, suggesting that these residues directly interact with the ligand.
Total fluorescent measurements in each capillary further suggested how the ligand
may be interacting with the receptor in the binding pocket. For most of the samples, the
fluorescence in each capillary remained constant as the ligand concentration was
increased. However, for the F256L variant, the fluorescence decreased linearly as the
heptanal concentration increased (Figure 7.5). Because all measured fluorescent signals
came from the protein tryptophans and are thus proportional to the receptor
concentration, these results demonstrate that the ligand is quenching fluorescence by
interacting with a tryptophan.
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Figure 7.4: Ligand-Binding Measurements of the Native mOR103-15 Receptor and the
Mutants. A) Native mOR103-15. Only one measurement was made to verify that this sample had
the same properties as the sample of mOR103-15 that was tested in Chapter 4. B) Heat-denatured
mOR103-15. C) mOR103-15 F262L. Only one measurement was obtained. D) mOR103-15 F256L. E)
mOR103-15 D204L. F) mOR103-15 L216V. G) mOR103-15 K164L H) mOR103-15 H181L. Most of
the mutated receptors did not demonstrate binding to heptanal, indicating that the substituted
residues interact with the ligand. Two mutants did show binding: D204L, F262L. Because the
observed half-maximal concentration was an order of magnitude higher in the F262L mutant
compared to the native protein, the residue F262 is also likely to be involved in receptor-ligand
interactions.
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Table 7.1: Measured ECso Values for mOR103-15 Mutants
Mutation in mOR103-15 EC 5 0 (sM)
Native Protein 1.4± 0.7
Denatured Native Protein No binding
K164L No binding
H181L No binding
D204L 1.6 ±-0.7
L216V No binding
F256L No binding
IF262L 18.5 -- 3.8
mORlO3-15 F262L
0 0
Heptanal Concentration (jAM)
mOR103-15 F256L
x 10'
Heptanal Cce 10 ( yM
Heptanal Concentration ( tiM)
Figure 7.5: Fluorescence Signal as a Function of Heptanal Concentration. A) The signal for the
F262L Mutant. B) The signal for the F256L Mutant. In the F256L mutant samples, the fluorescence
signal is quenched as the heptanal concentration increases. This indicates that the ligand is directly
interacting with a tryptophan in the receptor. The fluorescence signal in the mutant F262L does
not vary with heptanal concentration, and this behavior is representative of the remaining mutants
as well as the native protein. This further demonstrates that the quenching observed with the
F256L mutant results from a heptanal-tryptophan interaction that depends on the residue position
256, and not the amino acid.
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7.4 Discussion
7.4.1 Molecular Interactions Involved in Olfactory Receptor Ligand Binding
The results presented in this study suggest which residues may be involved in
ligand binding in mOR103-15, as well as other olfactory receptors.
Based on computational analyses, several groups of researchers have reported that
residue K164 recognizes odorants through hydrogen bonds, or potentially by forming a
Schiff base [18, 19, 21]. One study also suggested that the residue D204 participates in this
interaction, either through repulsive forces that prevent a strong interaction between the
ligand and K164, or by stabilizing the putative Schiff base [21]. Modeling in this latter
study further predicted that ligand affinity would decrease if K164 were mutated to an
alanine, while the affinity would increase if D204 were mutated to an alanine. The data in
Figure 7.4 suggests that K164 is indeed involved in ligand recognition, as mutation to a
leucine abolished a response to heptanal. However, mutation of D204 to a leucine did not
affect the ligand affinity (Table 7.1), indicating that this residue is not involved in binding
heptanal. Interestingly, the alignment position of K164 in other olfactory receptors often
has either a histidine or glutamine, or a straight-chain hydrophobic residue. It is likely that
this represents a key position in many olfactory receptors that is involved in ligand
recognition. Indeed, several computational studies predict that the histidine at this
alignment position is involved in ligand binding [16,21]. Lysine, histidine, and glutamine
can form hydrogen bonds, and are probably involved in recognizing specific functional
groups on odorants. In contrast, receptors with a hydrophobic residue at this alignment
position have probably evolved to recognize different odorant functional groups.
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Figure 7.6: Alignment of mOR103-15 with 9 Olfactory Receptors and 4 GPCRs with Known
Structures. A) Region Surrounding K164, B) Region Surrounding H181, C) Region Surrounding
L216, and D) Region Surrounding F256 and F262. The position to the right of F256 contains a
tryptophan that is conserved in most GPCRs, and a tyrosine that is conserved in ORs. The residues
mutated in this study are in red, the alignment position is highlighted in yellow and residues
experimentally shown to bind ligands in other receptors are in blue. Alignments were performed
by ClustalW [34].
The results in Figures 7.4 and 7.5 indicates that the residue F256 interacts with the
ligand heptanal, and may even be a conserved ligand-recognition site in the OR family.
Mutation of this phenylalanine to a leucine abolished a binding response that could be
detected by thermophoresis. Moreover, heptanal was able to interact with a tryptophan in
the mutated protein and quench its fluorescence. The receptor mOR103-15 has two
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tryptophans. One is located in the second transmembrane helix (W73), and the other is in
the fourth transmembrane helix (W154). Several groups predict that W73 faces the cell
membrane, while W154 faces the binding pocket [14, 21]. Also, W154 is conserved not
only in olfactory receptors, but in the GPCR family as well, suggesting that it may play a
critical structural or functional role. Taken together, this suggests that heptanal is
interacting with W154, and that F256 and W154 are vertically aligned or in close
proximity. Perhaps F256 acts as a gate; upon ligand binding, it is somehow able to change
conformation and interact with W154, enabling cell-signaling. When this molecular "gate"
is removed by substituting in a leucine, the ligand can freely and directly access underlying
tryptophan. Interestingly, a tryptophan that is generally conserved among GPCRs in the
sixth transmembrane region is believed to form a "toggle" switch necessary for receptor
activation [8, 27-29]. In olfactory receptors, a tyrosine typically occupies this conserved
position. It is possible that this tyrosine functions as a toggle switch in olfactory receptors,
but it is also possible that a different molecular mechanism exists. It should be noted that
the proposed mechanism does imply ligand-receptor binding, and that none was detected.
However, it's possible that the fluorescence quenching is masking any thermophoresis
signal. Also, because no olfactory receptor structure exists, the possibility of an interaction
with W73 cannot be discounted. The transmembrane regions are based on modeling
predictions, and a difference of even a few residues in the transmembrane helix boundaries
can change the relative orientations of these residues. It is thus possible that W73 does
face the binding pocket. Interestingly, the residue F256 in mOR103-15 corresponds to the
residue F252 in mOR174-9, and is conserved throughout the OR family (Figure 7.6). A
mutational study demonstrated that substituting F252 in mOR174-9 with a leucine
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decreased its responsiveness to its ligand two-fold [10]. Because this residue is involved in
ligand recognition in at least one olfactory receptor, and because the residue is conserved
in the OR family, it is likely to be involved in ligand-binding in other olfactory receptors.
The residue F262 is also conserved in ORs, and is aligned near two phenylalanines
in the p1- and p2-adrenergic receptors that are involved in ligand-binding (Figure 7.6).
Although the adenosine A2A receptor and rhodopsin do not have phenylalanines at this
location, the residues that do align with adrenergic receptor phenylalanines also interact
with the ligands of these receptors [5, 7, 8, 12]. Because ligand-binding residues are
perfectly aligned in transmembrane 6 in GPCRs whose crystal structures are known, it
seems probable that other GPCRs may have ligand-binding residues in the same region.
Thermophoresis data suggests that F262 is one such residue: the measured dissociation
constant increased by an order of magnitude when this residue was substituted with a
leucine (Table 7.1), suggesting weaker binding. Because binding was not completely
abolished, it is likely that this residue interacts with heptanal through van der Waals
interactions, or by physical interference. It is also possible that an F262L mutation alters
the local conformation of the receptor backbone, or the orientation of neighboring
residues, such that binding of heptanal is more constricted or less favorable. Indeed,
several reports predict that this residue faces the lipid bilayer [14, 21]. However, since no
OR structure exists, it is possible that F262 does actually face the binding pocket. Its close
alignment with ligand-binding residues in other GPCRs suggests that this may be the case.
Although it is located in the second extracellular loop (ECL2) instead of the ligand-
binding pocket (Figure 7.1), the residue H181 seems to be involved in ligand binding.
Indeed, ECL2 residues in other GPCRs are involved in ligand-receptor interactions, and
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H181 is closely aligned with these residues. It is well known that strong odors are good
ligands for metal ions [17, 30], and that histidines can coordinate metals and typically
comprise metal-binding domains in proteins [31]. These observations suggest that
olfactory receptors are metalloproteins, and that a conserved histidine like H181 may
coordinate metal ion interactions that in turn affect ligand binding or sensitivity. Indeed,
one study has shown that the conserved motif in which H181 is located (HFFCD/E) is
capable of binding metal ions [17]. Taken together, this suggests that H181 may affect OR-
odorant sensitivity by coordinating with metal ions. Replacing H181 with a leucine
prevents this interaction. It is also possible that H181 directly interacts with the ligand,
and future studies must be performed to elucidate its role. Since the ECL2 ligand-binding
residues in other GPCRs are primarily phenylalanines or glutamic acid, and these residues
are also located near H181, it is possible that H181 only neighbors the actual ligand-
binding residue and that an H181L substitution alters the loop conformation in a way that
inhibits binding.
The residue L216 also appears to be involved in ligand recognition, as mutation to
valine prevents binding to heptanal (Figure 7.4). This residue is in a hypervariable region
[14], and is aligned to a leucine in mOR174-9 that has been shown to be involved in ligand
binding [10]. This suggests that this particular residue position may be critical for ligand
recognition in other ORs as well, and that it likely either interacts through hydrophobic or
van der Waals interactions instead of recognizing functional groups on odorants.
Taken together, the binding results presented here, as well as sequence alignments
and published mutational studies, suggest that some residues or key alignment positions
may be involved in ligand binding in all or most ORs. Most of the residues implicated in
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binding in this study are either conserved throughout the entire OR family, or are aligned
with residues with similar properties. The specific physical or chemical properties of these
amino acids may thus determine which functional groups are recognized on odorants, and
how the odorants are situated within the binding pocket. This, in turn, would determine
the extent of odorant-activated signal transduction.
7.4.2 An Efficient Method for Parallel Screening of Multiple GPCRs
The results reported in this chapter demonstrate that the methods developed in
Chapter 4 constitute a relatively high-throughput method for producing ORs and studying
their function. The large number of receptors that could be produced further suggests that
the technique can be extended to other GPCRs, and potentially other membrane proteins.
However, in order to verify binding measurements made with purified receptors, and to
completely understand their biological function, calcium influx assays must also be
conducted. It is possible for a ligand to bind to a receptor, yet not initiate a signal. This can
happen if the ligand is an antagonist [32], or if a minimal energy barrier has not been
reached [22]. Conversely, it may be possible for a ligand to initiate a signal, yet not bind in
a detectable manner due to a low affinity, or high noise-to-signal ratio. Also, because the
lipid bilayer exerts mechanical forces on proteins found within it, it is possible that the
conformation of a receptor may change slightly yet significantly when it is transferred to a
detergent environment, thus changing its binding affinity. Nevertheless, it is now possible
to simultaneously express and purify multiple mutants using cell-free technology, and
screen these mutants for potential ligand binding activity. Promising mutants can then be
selected, and further tested in cells.
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